  
 
 
 
 
 
 
Protocol  
 
 
Title of  trial:   
A Multicenter, Double -Blind, Randomized, Placebo -Controlled Study 
Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered via 
OmniPod Pump for Ovulation Induction in Female Subjects with Primary 
Amenorrhea with Hypogonadotropic Hypogonadism   
NCT n umber : 
[STUDY_ID_REMOVED]  
Sponsor trial c ode: 
000070  
Date:  
06 Dec 2017  
 
 
 
 
 

Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 1 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL   
 
CLINICAL TRIAL PROTO COL  
 
 
A Multicenter, Double -Blind, Randomized, Placebo -Controlled Study Evaluating T hree  Doses 
of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction 
in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism  
 
Trial Code 000070  
 
Consolidated Proto col Incorporating Amendments 1 -7 
 
 
IND Number:  22,[ADDRESS_272881]:  LutrePulse OmniPod  
Indication:  Primary Hypothalamic Amenorrhea  
Phase:  III 
Name [CONTACT_2259]:  Ferring International Pharmascience Center U.S., Inc.  
[ADDRESS_272882]  
Parsippany, NJ [ZIP_CODE]  
P: 973 -796-1600  
F: 973 -796-1660 
GCP Statement:  This trial will be performed in compliance with GCP.  
 
 
 
 
 
The information in this document is confidential and is proprietary to Ferring International Pharmascience Center U.S. or 
another company within the  Ferring Group.  It is understood that information in this document shall not be disclosed to 
any third party, in any form, without prior written consent of an authorized officer of Ferring International Pharmascience 
Center U.S. or another company within the Ferring Group.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 2 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272883] visit (FSFV)  March [ADDRESS_272884] visit (LSLV)   June 2019  CLINICAL PHASE  
III 
OBJECTIVES  
Primary objective  
‚Ä¢ To compare the ovulation rate in women with  primary amenorrhea with  hypogonadotropic 
hypogonadism (HH) following each of three doses (10 ÔÅ≠g, 15 ÔÅ≠g, and 20 ÔÅ≠g per pulse) of 
subcutaneous (SC)  pulsatile gonadotropin -releasing hormone (GnRH) administered with 
the LutrePulse OmniPod Pump versus placebo  
Secondary objectives  
‚Ä¢ To evaluate clinical pregnancy rate  
‚Ä¢ To evaluate biochemical pregnancy rate  
‚Ä¢ To evaluate LH surge rate 
‚Ä¢ To evaluate ovarian follicular development  
‚Ä¢ To evaluate luteal phase support with GnRH    
‚Ä¢ To eval uate pharmacodynamic parameters  
‚Ä¢ To evaluate the safety of LutrePulse OmniPod SC  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 3 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  ENDPOINTS  
Primary endpoint  
‚Ä¢ Ovulation rate, calculated as a proportion of subjects with at least [ADDRESS_272885] -baseline 
progesterone (P 4) level ‚â•  6 ng/mL or a confirmed positive serum Œ≤ -hCG (i.e., 2 positive 
results) or presence of a gestational sac documented by [CONTACT_226951] (TVUS)  
Secondary en dpoints  
Progesterone levels:  
‚Ä¢ Proportion of subjects with at least [ADDRESS_272886] -baseline P 4 level ‚â•  10 ng/mL  
Pregnancy:  
 Clinical pregnancy rate:  
‚Ä¢ Proportion of subjects with presence of gestational sac and fetal heart movement (FHM) 
on transvaginal ultrasound (TVUS) at approximately 2 to 4 weeks after a second positive 
serum beta human chorionic gonadotropin ( ÔÅ¢-hCG) test  
 Biochemical pregnancy rate:   
‚Ä¢ Proportion of subjects with a confirmed positive serum ÔÅ¢-hCG (i.e., 2 positive results) 
14 + [ADDRESS_272887] luteini zing hormone (LH) surge  
LH Surge Detection :  
‚Ä¢ Proportion of subjects with a positive detection of LH surge on a Clearblue test  
Ovarian Follicular Development:  
‚Ä¢ Number of follicles with a mean diameter ‚â• 14 mm  
‚Ä¢ Number of dominant follicles with a mean diameter ‚â• 18 mm  
Luteal Phase Support:  
‚Ä¢ Maximum P 4 levels from Days 19, 21, 23, 25, and 27  
‚Ä¢ Mean P 4 levels from Days 19, 21, 23, 25, and 27  
Pharmacodynamic Endpoints:  
‚Ä¢ Follicle -stimulating hormone (FSH) and LH change from baseline in relation to the first 
GnRH pulse on Day 1 and Day 10  
‚Ä¢ Mean serum FSH and LH levels on Day 1 and Day 10  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 4 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ Estradiol (E 2) serum levels on Day 1 and Day 10  
Safety Endpoints:  
‚Ä¢ Adverse events (type, frequency, intensity, and seriousness)  
‚Ä¢ Clinical chemistry, hematology, urinalysis  
‚Ä¢ Frequency and severity of ovarian hyperstimulation syndrome (OHSS)  
METHODOLOGY  
This multicenter, randomized, double -blind, placebo -controlled study will be performed in 
approximately [ADDRESS_272888], therapy should be continued for approximately 
another 2 weeks to maintain corpus luteum  function  (continue until confirmatory serum 
pregnancy test).  Subjects will discontinue treatment either at the onset of menses or after having 
two (2) negative or two (2) positive confirmatory serum pregnancy test s. Subjects will be 
required to return to the study site for pharmacodynamic blood draws, TVUS, serum pregnancy 
tests, and safety follow -up assessments.  
The study will consist of 3 periods: Screening (includes progestin challenge test), Treatment 
(includes pi[INVESTIGATOR_226931]), and Follow -up. 
Screening (Day -60 to Day -1): Only subjects with diagnosed primary amenorrhea with HH 
should be screened.  Only subjects who desire p regnancy will be eligible to participate in the trial.  
The site will obtain written informed consent before any study -related procedures begin.  Upon 
signing the Informed Consent Form, subjects will be screened based on inclusion/exclusion 
criteria.  The a ssessments during the screening period will include medical/gynecologic history, 
safety laboratory tests (chemistry, hematology, urinalysis), other laboratory tests (serum 
pregnancy, LH, FSH, E 2, P4, prolactin [PRL], and thyroid -stimulating hormone [TSH] l evels), 
vital signs (blood pressure, heart rate, body temperature),  Papanicolaou (PAP) smear (if not done 
within the last 24  months; PAP smear may be performed at Screening and for every patient if 
warranted, per investigator discretion), TVUS documenting  normal uterus and adnexa, and a 
physical/gynecological examination.  A normal or stable computed tomography (CT) scan or 
magnetic resonance imaging (MRI) scan of the hypothalamic pi[INVESTIGATOR_226932].  T he male partner should have a recent normal semen 
analysis (within 1 year). A progestin challenge test will also be initiated to confirm HH.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 5 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  Rescreening will be allowed at the investigators‚Äô discretion for subjects who exhibit laboratory 
tests outside of t he normal or required range.  No subject may be rescreened more than once.  
Rescreening for the progestin challenge test is not allowed.  
Progestin challenge test :  After confirmed negative serum pregnancy test, subjects will be 
dispensed 10 mg of medroxypr ogesterone acetate (Provera¬Æ) once daily for [ADDRESS_272889] dose of progestin will 
continue to the treatment period.  Per investigator‚Äôs discretion, occasional spotting is not 
considered withdrawal  bleeding.  Subjects with uterine bleeding are considered screen 
failures and will be ineligible for study participation.   Rescreening for the progestin 
challenge test is not allowed.  
Treatment (Day 1 to approximately Day 37) : Subjects who do not have uter ine bleeding within 
[ADDRESS_272890] dose of progestin will return to the clinic; a negative urine pregnancy test 
result is required and then the subject will be randomly assigned to 1 of 4 treatment arms: 
LutrePulse OmniPod SC 10 Œºg/pulse, 15 Œºg/puls e, 20 Œºg/pulse, or placebo (10, 15, or 20 Œºg/pulse 
delivery setting) every [ADDRESS_272891] OmniPod pump 
will be applied on Day 1.  Each OmniPod pump will be worn for 3 days (Days 1 -3, 4-6, 7-9, etc. 
to approximately Day 37).  The subject will apply subsequent OmniPod pumps every 4th day at 
approximately the same time as the 1st application  (¬±1 hour) . 
Pharmacodynamic assessments :  A blood sample for E 2, LH and FSH will be taken on 
Day 1 (pre -treatment baseline) prior to dosing.  Additional blood samples for only LH and 
FSH will be taken 5, 15, 30, 60, and [ADDRESS_272892] dose is administered.   
A blood sample for E 2, LH and FSH will be taken on Day 10 at the same time as the  Day 1 
initial sample (¬±1  hour) and before the first dose is administered by [CONTACT_48657] [ADDRESS_272893] dose is administered.  
 
 
 
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 6 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  Follicular and endometrial dev elopment: Follow -up will begin on Day 10 of treatment.  
Follicular and endometrial development will be monitored by [CONTACT_226952]‚Äôs discretion (minimum of 3 TVUS), until a dominant follicle of ‚â• 18 mm mean 
diameter and normal  endometrium (thickness and pattern) are confirmed. If a dominant follicle ‚â• 
18 mm mean diameter is not observed after 21 full days of treatment, the therapy will be 
discontinued .  However, the treatment may be continued for a maximum of 3 9 days at the 
discretion of the investigator if the patient has growing follicle(s) .  After Day 10, a single blood 
sample for E [ADDRESS_272894] 
who has an increased risk of developi[INVESTIGATOR_226933]/OHSS (4 or more follicles with a 
mean diameter ‚â•  15 mm by [CONTACT_226953] E 2 levels ‚â•  1200 pg/mL) will be discontinued from 
treatment.  
LH surge detection:  Clearblue¬Æ digital ovulation urine test will begin when follicles with a 
mean diameter ‚â• [ADDRESS_272895] ( Appendix II). 
The subject should notify the site immediately once the surge has been detected to schedule 
a visit within 72 hours for a confirmatory TVUS.  Subjects will be advised to engage in 
sexual intercourse on the day of LH surge, the day following LH surge, an d per 
investigator‚Äôs discretion thereafter. The subject should also document the date(s) of sexual 
intercourse on the subject diary card.  
If LH surge is not detected  after [ADDRESS_272896] will be discontinue d.  
However, the treatment m ay be continued for a maximum of 3 9 days at the discretion of the 
investigator if the patient has growing follicle(s) .The subject will be instructed to visit the 
site to return all study drug and the OmniPod System.  
Blood samples for progesterone (P 4) leve ls: A single blood sample for P 4 will be taken on 
Day 1 (pre -treatment baseline) prior to dosing.  Blood samples will also be obtained on Day 
19, Day 21, Day  23, Day [ADDRESS_272897] discontinued the study 
early and ended treatment on or after Day 14, a blood sample will also be taken at the End-
of-Study Visit .   
Menses Onset:   Subjects who begin menstruating after treatment was initiated will be 
instructed to stop the treatment and to visit the site to return all study drug and the OmniPod 
System.  The site will record the first day of menses and duration of menses for all non -
pregnant subjects.   
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 7 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  Serum pregnancy tests ( ÔÅ¢-hCG):  will be performed 14 days (+ 4 days) after LH surge and 
3 days thereafter.  Two positive pregnancy tests are required to confirm biochemical 
pregnancy.  If only one of the 2  tests is positive, the subjec t will return within 5 days 
(unscheduled visit) to confirm pregnancy with another test.  
After obtaining two (2) negative or two (2) positive confirmed serum pregnancy test results, the 
treatment will complete.   
All subjects will be assessed for an End -of-Study visit and return all study drug and the OmniPod 
System.  
Follow -up:  TVUS for pregnancy outcome:  Subjects who achieve pregnancy (2 positive serum 
pregnancy tests) will be followed up for clinical pregnancy (gestational sac and fetal heart 
movement) [ADDRESS_272898] data for ongoing pregnancy rate (fetal heart movement at 
gestational Week 11 or Week 12), including safety follow -up of the subjects for miscarriage, fetal 
anomalies and live birth rate.  
NUMBER OF SUBJECTS  
Approximately 60 female subjects will be randomized.   
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 8 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  MAIN CRITERIA FOR INCLUSION / EXCLUSION  
Inclusion Criteria:  
1 Signed written informed consent prior to any study -related procedure  
2 Women 18 - 40 years old  
3 Body mass index (BMI) between 18 and 38 kg/m2 
4 Documented clinical history or recently diagnosed with primary amenorrhea with 
hypogonadotropic hypogonadism  
5 Hormonal values in a centrally analyzed fasting blood sample: FSH < 5 IU/L and mean 
LH < 5 IU/L  
[ADDRESS_272899] performed during screening  
9 Normal PAP smear within 24 months of the initial visit (PAP smear can be performed at  
Screening, per investigator discretion  and standard of practice  if warranted, even if results 
within 24 months are available)  
[ADDRESS_272900] year  
13 Normal TVUS at Screening with respec t to uterus and adnexa (presence of both ovaries 
and tubes, without evidence of clinically significant abnormality) and with normal uterine 
cavity, normal cervix  
[ADDRESS_272901] 2  years  
15 Willing and able to comply with the protocol for the duration of the study  
 
Exclusion Criteria:  
1 Any medical condition that, in the judgment of the investigator, may interfere with the 
absorption, distribution, metabolism, or excretion of the drug  
2 A history of or currently diagnosed with clinically important cardiovascular, pulmonary 
(e.g., serious corticosteroid -dependent asthma), gastrointestinal, hepatic, metabolic, renal, 
endocrinological (e.g., insulin -dependent diabetes mellitus), or neurological (e.g., 
epi[INVESTIGATOR_002], serious migraine, central nervous system [CNS] lesions [in cases where HH is 
secondary to a CNS lesion or its treatment]) abnormality   
[ADDRESS_272902] 2 months  
5 Known allergy to study drug or its components  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 9 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  6 Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C  
[ADDRESS_272903] of unknown etiology  
8 Abnormal gynecological  bleeding of undetermined origin  
9 Previous or current hormone -dependent tumor  
10 Known active substance abuse  
11 Planning to undergo in vitro fertilization procedure in the course of a study treatment 
cycle  
12 Currently undergoing treatment with gonadotropin hormon es (FSH and LH), psychotropic 
medication, sex hormones, or any other medication known to interfere with normal 
reproductive function or that can affect GnRH secretion (e.g., neuroleptics, dopamine 
antagonists, spi[INVESTIGATOR_8407], levodopa, phenothiazine, digox in) 
13 Ongoing pregnancy or lactation  
14 Participation in any experimental drug study within 30 days prior to screening  
15 Previously randomized in this study  
16 The patient is considered by [CONTACT_226954] r eason  
17 The patient has a mental incapacity or language barrier precluding adequate understanding 
or cooperation . 
MEDICINAL PRODUCTS  
LutrePulse (gonadorelin acetate) for subcutaneous (SC) p ulsatile injection via OmniPod S ystem, 
delivering [ADDRESS_272904] (IMP) : 
‚Ä¢ Lutrelef 3.2 mg, lyophilized powder for reconstitution  
‚Ä¢ Solvent in vials of [ADDRESS_272905] ( NIMP ): 
‚Ä¢ Provera¬Æ (medroxyprogesterone acetate tablets, USP) 10 mg  
Device:  
‚Ä¢ Delivery pump (OmniPod) for administration of IMP  
‚Ä¢ Managers for programming of the delivery pump  
‚Ä¢ Syringes, needles and adaptors used for reconstitution and loa ding of delivery pump  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 10 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  DURATION OF TREATMENT  
LutrePulse (gonadorelin acetate) delivered via pulsatile injection every 90 minutes (1 -minute 
delivery followed by [CONTACT_1629] 89 -minute gap) for a total of approximately [ADDRESS_272906] response; 
it is expected that follicular  response to LutrePulse will occur within 2 to 3 weeks after therapy 
initiation.  However, the treatment may be continued for a maximum of 3 9 days at the discretion 
of the investigator if the patient has growing follicle(s).   Additionally, w hen ovulation occurs, 
therapy should be continued for approximately another 2 weeks to maintain corpus luteum  
function  (continue until confirmatory serum p regnancy test) .   
STATISTICAL METHODS  
Sample size :  
The sample size was determined based on the original fixed parallel group study design. The true 
ovulation rate for LutrePulse OmniPod SC 20 Œºg, 15 Œºg, 10 Œºg, and placebo was assumed to be 
70%, 65%, 60%,  and 1%, respectively.  Under these assumptions, a sample size of 14 subjects 
per group (total 56  subjects) will provide at least 80% power to detect differences between 
LutrePulse OmniPod SC 20 Œºg and placebo, 15 Œºg and placebo, and 10 Œºg and placebo in 
ovulation rate separately  using stratified one -sided Fisher‚Äôs exact tests19 at an overall one -sided 
significance level of 0.025  with the closed testing procedure (Kong et al., 2005)18 to be used for 
the primary efficacy a nalysis.   
Approximately 60  subjects will be randomized, assuming up to 4 subjects may be ineligible for 
the full analysis set (FAS).  
Efficacy :  
The primary efficacy analysis will be based on all randomized subjects who received at least 14 
days of study d rug for pi[INVESTIGATOR_226934] (i.e., FAS).  
The primary efficacy endpoint will be ovulation rate calculated as the proportion of subjects who 
had at least [ADDRESS_272907]-baseline value of P 4 level ‚â•  6 ng/mL  or pregnancy  confirmed by a positive 
serum Œ≤ -hCG (i.e., 2 posi tive results) or presence of a gestational sac documented by [CONTACT_226955] (TVUS) .  A Bayesian adaptive design is adopted to address the following objectives:  
1. Demonstrate superiority of the pooled middle and high doses over placebo  in the 
ovulation rate  
2. Evaluate  the dose -response relationship  
The adaptive design includes two interim analyses, conducted after approximately 9 and 12 
patients per arm enrolling in the study, respectively. The interim analysis provides an opportunity 
for stoppi[INVESTIGATOR_226935]. Furthermore, it allows the  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 11 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  low dose to be dropped following the interim look if it shows a much lower response rate 
compared with the middle and high doses .  
Each interim analysis will result in one of the following  possible  outcomes:  
1. Continue the trial with all arms  
2. Continue the trial without the low dose  
3. Declare early success,  but continue the trial without placebo  
4. Declare early success and stop the trial (both placebo and low dose dropped)  
5. Stop the trial for futility  
When  the primary efficacy analysis is not successful at the interim analysis, and if the ovulation 
rate i n the low -dose arm is sufficiently low, satisfying  
                                           Rlow < (R high +middle ) ‚Äì 0.2,                                                      (1)  
then the trial will continue without the low dose, resulting in outcome #2 listed above. Note that 
Rlow and Rhigh +middle  in inequality (1)  are the observed ovulation rates in the low dose arm and the 
combined middle - and high -dose arms, respectively. However, if inequality (1) is not satisfied, 
then the trial will continue with all arms (outcome #1  listed above ).  
Conversely, when success on the primary efficacy analysis is declared at an interim analysis, if 
the response rate in the low -dose arm meets the condition in inequality (1), then the trial is 
completed at this point (ou tcome #4  listed above ) with dose selection using the ED80 rule (see 
below).   
In the case the primary efficacy analysis is successful, but the response rate in the low -dose arm 
is within 20% from the combined low - and high -dose success rate, the trial is not stopped 
immediately. Rather, the trial will continue to enroll additional p atients into the low -, middle - and 
high-dose arms to further assess dose responses.  
Finally, the trial may terminate (outcome #5  listed above ) as a result of a low predictive 
probability of success (<0.05) given the data collected at the interim analysis.   
At the end of the study, for a trial that achieves efficacy success, the dose to be selected as the 
lowest effective dose is the ED80 dose, defined as the lowest dose that retains at least 80% of the 
largest treatment effect, i.e.  
                                  (RED80 ‚Äì Rplacebo ) ‚â• (R maximum  ‚Äì Rplacebo ) √ó0.8,                                   (2)  
where R maximum  is the observed ovulation rate in the most effective dose arm, R placebo  is the 
observed ovulation rate in the placebo ar m, and R ED80 is the observed ovulation rate in the 
selected dose arm.  
The primary efficacy analysis will compare the pooled ovulation rate of LutrePulse OmniPod SC 
20 ÔÅ≠g and 15 ÔÅ≠g to placebo. Let Phigh+middle  and  Pplacebo  be the underlying ovulation rates in the 
combined middle - and high -dose arms and the placebo arm, respectively. The hypotheses for the 
one-sided statistical testing are:  
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 12 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  ùêª0:ùëÉ‚Ñéùëñùëî‚Ñé+ùëöùëñùëëùëëùëôùëí ‚â§ ùëÉùëùùëôùëéùëêùëíùëèùëú , 
vs. 
ùêª0:ùëÉ‚Ñéùëñùëî‚Ñé+ùëöùëñùëëùëëùëôùëí > ùëÉùëùùëôùëéùëêùëíùëèùëú . 
The hypotheses are tested using a stratifie d one -sided Fisher‚Äôs exact test (Jung et al., 2014) in the 
FAS including the randomization scheme as the stratification factor. The SAS PROC FREQ with 
permutation -based Cochran -Mantel -Haenszel test with exact p -value derived from all possible 
permutations  will be employed for the calculation of p -value for the stratified Fisher‚Äôs exact test.  
To account for the multiplicities introduced by [CONTACT_226956],  Pocock boundaries 
are used. Thus, t he success threshold at each analysis corresponds to a  nominal p -value < 0.0131 
to maintain an overall one -sided type I error rate of 0.025.  
Sensitivity analysis:  
‚Ä¢ will be performed  on the PPS  
‚Ä¢ will be performed on the mITT  
For the secondary efficacy analyses, clinical and biochemical pregnancy rates will be compared 
between the pooled middle - and high-dose arms vs. the placebo arm  using the same statistical 
method to be applied to the primary efficacy analysis.  Numbers of follicles with a mean diameter 
‚â• 14 mm and dominant follicles with a mean diameter ‚â•18  mm will be compared using 
Wilcoxon‚Äôs rank sum test by [CONTACT_226957].  The maximum P 4 
level and the mean P 4 level from Days 19, 21, 23, 25 , and 27  values will be compared using an 
analysis of covariance (ANCOVA) model including the treatment group and  randomization 
scheme as factors and mean baseline value as covariate.  The proportion of subjects with at least 
[ADDRESS_272908] -baseline progesterone ( P4) level ‚â•  10 ng/mL will be compared to placebo using the same 
statistical method to be applied to the primary efficacy analysis. The mean FSH and LH on Day 
10, as well as the change from baseline, will be compared using ANCOVA model  including the 
treatme nt group and randomization scheme as factors and mean baseline value as covariate.   The 
E2 levels on Day 10, as well as the change from baseline, will be compared using a similar 
ANCOVA model.  The change in the maximum value of FSH, LH, and E [ADDRESS_272909] value taken on Day 1 and Day 10, respectively, will be presented with 
descriptive statistics by [CONTACT_1570].  The FSH, LH, and E 2 levels on Day 1 and Day 10 will 
be presented graphically by [CONTACT_1570].  
Safety:  
Safet y parameters will be summarized by [CONTACT_226958] 1 
pulsatile injection delivery of study drug.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 13 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272910] OF ABBREVIATIONS AND DEFINITION OF TERMS  17 
1 INTRODUCTION  19 
1.1 Background  ................................ ................................ ................................ ............. 19 
1.2 Scientific Justification for Conducting the Study  ................................ ........................... 20 
2 STUDY OBJECTIVES AND ENDPOINTS  21 
3 INVESTIGATIONAL PLAN AND STUDY DESIGN  23 
3.1 Overall Design and Plan ‚Äì Description ................................ ................................ ......... [ADDRESS_272911] (IMP)  ................................ ..........................  [ADDRESS_272912] (NIMP)  ................................ .................  [ADDRESS_272913] ................................ .............................  33 
5.3 Conditions for Storage and Use ................................ ................................ ................... 33 
5.4 Blinding / Unblinding ................................ ................................ ................................ [ADDRESS_272914] Treatment  ................................ ......................  35 
5.5 Selection of Doses in the Study ................................ ................................ ................... 36 
5.6 Treatment Compliance  ................................ ................................ .............................. 37 
5.6.1  Dispensing and Accountability  ................................ ................................ ........  37 
5.6.2  Assessment of Compliance  ................................ ................................ .............  37 
5.7 Auxiliary Supplies  ................................ ................................ ................................ ....37 
5.8 Return and Destruction of Medicinal Products and Auxiliary Supplies  .............................. 37 
6 STUDY FLOW CHART AND STUDY PROCEDURES  39 
6.1 Schedule of Activities  ................................ ................................ ............................... 39 
6.2 Study Procedures ................................ ................................ ................................ ......42 
6.2.1  Screening/Pre -treatment  ................................ ................................ .................  42 
6.2.2  Treatment Day 1 through Day 10 ................................ ................................ ..... 43 
6.2.3  Treatment Day 11 until LH Surge  ................................ ................................ .... 44 
6.2.4  Progesterone and Pregnancy Monitoring ................................ ...........................  45 
7 STUDY ASSESSMENTS  48 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 14 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272915] Disposition  ................................ ................................ ................................ ...62 
9.3 Protocol Deviations  ................................ ................................ ................................ ..62 
9.4 Analysis Sets  ................................ ................................ ................................ ........... 62 
9.4.1  Intent -to-Treat (ITT) Analysis Set ................................ ................................ .... 62 
9.4.2  Full Analysis Set (FAS)  ................................ ................................ .................  62 
9.4.3  Modified Intent -to-Treat (mITT) Analysis Set  ................................ ...................  62 
9.4.4  Per Protocol Set (PPS)  ................................ ................................ ...................  63 
9.4.5  Safety Population  ................................ ................................ ..........................  63 
9.5 Trial Population  ................................ ................................ ................................ ....... 63 
9.5.1  Demographic and Baseline Characteristics  ................................ ........................  63 
9.5.2  Medical History and Concomitant Medications ................................ ..................  63 
9.6 Efficacy Endpoint Assessments  ................................ ................................ .................. 63 
9.6.1  General Considerations  ................................ ................................ ..................  63 
9.6.2  Primary Efficacy Endpoint  ................................ ................................ .............  64 
9.6.3  Secondary Efficacy Endpoints ................................ ................................ .........  65 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 15 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272916] OF THE TRIAL  72 
12.1  Protocol Amendments  ................................ ................................ ............................... 72 
12.2  Deviations from the Protocol  ................................ ................................ ...................... 72 
12.3  Premature Trial Termination  ................................ ................................ ...................... 72 
13 REPORTING AND PUBLICATION  73 
13.1  Clinical Trial Report  ................................ ................................ ................................ .73 
13.2  Confidentiality and Ownership of Trial Data ................................ ................................ .73 
13.3  Publications and Public Disclosure  ................................ ................................ .............. 73 
13.3.1  Publication Policy  ................................ ................................ .........................  73 
13.3.2  Public Disclosure Policy  ................................ ................................ ................  73 
14 ETHICAL AND REGULATORY ASPECTS  74 
14.1  Independent Ethics Committee (IEC) or Institutional Review Board (IRB)  ........................ 74 
14.2  Regulatory Authorities Authorization / Approval / Notification  ................................ ....... [ADDRESS_272917] Information and Consent  ................................ ................................ ................ 74 
14.6  Compliance Reference Documents  ................................ ................................ .............. 75 
15 LIABILITIES AND INSURANCE  76 
15.1  ICH-GCP Responsibilities  ................................ ................................ ......................... 76 
15.2  Liabilities and Insurance  ................................ ................................ ............................ 76 
16 ARCHIVING  77 
16.1  Investigator File  ................................ ................................ ................................ ....... 77 
16.2  Trial Master File ................................ ................................ ................................ ....... 77 
17 REFERENCES  78 
18 APPENDICES  80 
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 16 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272918] of Figures  
Figure 1: The OmniPod Drug Delivery System  ................................ ................................ ............ 32 
 
Appendices  
Appendix I ‚Äì Subject‚Äôs Confidential Non -Disclosure Affidavit  ................................ ..................... 80 
Appendix II ‚Äì Subject Diary Card ................................ ................................ ................................ 81 
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 17 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272919] OF ABBREVIATIONS AND  DEFINITION OF TERMS  
Abbreviations  Meaning of abbreviations in document  
AE adverse event  
ANCOVA  analysis of covariance  
ATC  anatomical -therapeutic -chemical  
ÔÅ¢-hCG beta human chorionic gonadotropin  
BMI body mass index  
CNS  central nervous system  
CRF case report form  
CRO  contract research organization  
CT computed tomography  
E2 estradiol  
ECG  electrocardiogram  
eCRF  electronic case report form  
FAS Full Analysis Set  
FDA  Food and Drug Administration  
FHM  fetal heart movement  
FSH follicle -stimulating  hormone  
GCP  Good Clinical Practice  
GnRH  gonadotropin -releasing hormone  
HCP Healthcare Professional  
HH hypogonad otropic hypogonadism  
HIV human immunodeficiency virus  
ICH International Conference on Harmonisation  
ICMA  immunochemiluminometric assay  
IEC Independent Ethics Committee  
IFU Instructions for Use  
IMP Investigational Medicinal Product  
IRB Institutional Review Board  
ITT Intent -to-Treat  
IV intravenous  
LSLV  last subject last visit  
LH luteinizing hormone  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI magnetic resonance imaging  
NIMP  Non-Investigational Medicinal Product  
OHSS  ovarian hyperstimulation syndrome  
P4 progesterone  
PAP Papanicolaou  
PD pharmacodynamic  
PPS Per Protocol Set  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 18 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272920]  
US [LOCATION_002]  
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 19 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  1 INTRODUCTION  
1.1 Background  
Pulsatile gonadotropin -releasing hormone (GnRH) has been widely used in the [LOCATION_002] (US) 
and Europe for over [ADDRESS_272921] and a high degree of effectiveness in treating primary hypothalamic amenorrhea and 
in inducing ovulation and pregnancy in a variety of infertile patients.  Pulsatile GnRH is safer than 
other parenteral preparations and has a much lower incidence of inducing multiple pregnancies or 
ovarian hyperstimulation than other therapi[INVESTIGATOR_12985] -estrogens or gonadotropi[INVESTIGATOR_2115].1,2  
Hypogonadotropic hypogonadism (HH), characterized by [CONTACT_226959] (LH) and follicle -stimula ting hormone (FSH) in the setting of 
hypogonadism, may be amenable to treatment with GnRH.   
Several investigations utilizing subcutaneous (SC) administration of GnRH, including 
pharmacokinetic studies conducted by [CONTACT_2247], showed favorable GnRH and LH pro files and 
ovulation and pregnancy rates comparable to intravenous (IV) regimens.3,4,5,6,[ADDRESS_272922] approved in Europe as Lutrelef¬Æ in 1983 and as LutrePulse‚Ñ¢ in the US in 1989 and in 
Canada in 1993  with different pumps . 
LutrePulse (gonadorelin acetate) was approved in the US for use in patients with primary 
hypothalamic a menorrhea administered IV via the Zyklomat¬Æ pump, but was later withdrawn from 
the market for commercial reasons.  Therefore, no approved GnRH product is currently available 
for ovulation induction and treatment of primary hypothalamic amenorrhea patients in the US.   
LutrePulse (known as Lutrelef) with Om niPod for subcutaneous use was approved in [LOCATION_009] 
(2009), Netherlands (2010) and [LOCATION_013] (2011) to treat both men and women with GnRH 
deficiency or GnRH impairment.  In 2012 , Lutre Pulse ( gonadorelin acetate ) with the OmniPod 
device for subcutaneous administration was also approved and re -introduced in Canada for 
ovulation induction in patients with pri mary hypothalamic amenorrhea.  
The OmniPod¬Æ pump is a disposable SC delivery pump for LutrePulse with a hand -held wireless 
controller (the Manager).9  The OmniPod has been demonstrated to provide similar volume and 
similar bolus/pulse accuracy as the Zyklomat IV pump (data on file).  In addition, the stability of 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 20 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  LutrePulse solution over t he intended period of use was demonstrated for the OmniPod pump (data 
on file).  Compared to the IV pumps, the OmniPod SC pump with Lutre Pulse (Gonadorelin Acetate) 
represents a technologically advanced and more patient -friendly solution for pulsatile drug  delivery .  
If a successful efficacy and safety profile is established  for GnRH with the OmniPod , this will 
address the current unmet need in the very rare population of patients  with HH  in the US . 
1.[ADDRESS_272923] been previously reported in the literature for two IV doses of p ulsatile GnRH 
administered to GnRH -deficient women:  75 ng/kg (~3 -4 ¬µg/pulse) and 100 ng/kg (~5  ¬µg/pulse).8  
The recommended GnRH dose for primary hypothalamic amenorrhea women in the previously 
approved label for LutrePulse with IV pump was 5 ¬µg IV every 90 minutes, which could be 
increased up to 20 ¬µg in step wise fashion if there wa s no response.  The efficacy and safety of 10 
and 20 ¬µg/pulse administered SC in terms of ovulation induction w ere studied and published in 
literature in the past (See Section  5.5 for more details ) but there is currently  a need for a well -
powered and well -controlled , randomized  clinical trial to confirm the efficacy and safety profile of 
Lutre Pulse with OmniPod s ubcutaneous delivery pump .   
In addition to the 10 and 20 ¬µg/pulse doses, an intermediate dose of 15 ¬µg/pulse has been added to 
better understand the dose range.  This study is expected to provide much needed efficacy and 
safety information in this very ra re HH population of patients.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 21 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  2 STUDY OBJECTIVES AND ENDPOINTS  
Primary Objective  
‚Ä¢ To compare the ovulation rate in women with primary amenorrhea with hypogonadotropic 
hypog onadism (HH) following each of t hree doses ( 10 ÔÅ≠g, 15 ÔÅ≠g, and 20 ÔÅ≠g per pulse) of 
subcutaneous pulsatile gonadotropin -releasing hormone  (GnRH) administered with the 
LutrePulse OmniPod Pump versus placebo  
Secondary Objectives  
‚Ä¢ To evaluate clinical pregnancy rate  
‚Ä¢ To evaluate biochemical pregnancy rate  
‚Ä¢ To evaluate  LH surge rate  
‚Ä¢ To evalua te ovarian follicular development  
‚Ä¢ To evaluate luteal phase support with GnRH  
‚Ä¢ To evaluate pharmacodynamic parameters  
‚Ä¢ To evaluate the safety of LutrePulse OmniPod SC  
Primary Endpoint  
‚Ä¢ Ovulation rate, calculated as a proportion of subjects with at least [ADDRESS_272924]-baseline 
progesterone (P 4) level ‚â• 6 ng/mL  or a confirmed positive serum Œ≤ -hCG (i.e., 2 positive 
results) or presence of a gestational sac documented by [CONTACT_226951] (TVUS)  
Secondary Endpoints  
Progesterone levels : 
‚Ä¢ Proportion of subjects with at least [ADDRESS_272925] -baseline P4 level ‚â•  10 ng/mL  
 Pregnancy:  
  Clinical pregnancy rate:  
‚Ä¢ Proportion of subjects with presence of gestational sac and fetal heart movement 
(FHM) on transvaginal ultrasound (TVUS) at approximately 2 to 4  weeks after 
second positive serum beta human chorionic gonadotropin ( ÔÅ¢-hCG) test  
  Biochemical pregnancy rate:  
‚Ä¢ Proportion of subjects with a confirmed positive (i.e., 2 positive results) serum 
ÔÅ¢-hCG 14 + [ADDRESS_272926] LH surge  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 22 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL   LH Surge Detection :  
‚Ä¢ Proportion of subjects with a positive detection of LH surge on a Clearblue test  
Ovarian Follicular Development:  
‚Ä¢ Number of follicles with a mean diameter ‚â• 14 mm  
‚Ä¢ Number of dominant follicles with a mean diameter ‚â• 18 mm  
 Luteal Phase Support:  
‚Ä¢ Maximum P 4 levels from Days 19, 21, 23, 25 , and 27   
‚Ä¢ Mean P 4 levels from Days 19, 21, 23, 25 , and 27   
 Pharmacodynamic (PD)  Endpoints : 
‚Ä¢ FSH and LH change from baseline in relation to the first GnRH pulse on Day  1 and Day 
10  
‚Ä¢ Mean serum FSH and LH levels on Day 1 and Day  10 
‚Ä¢ Estradiol (E 2) serum levels on Day 1 and Day 10  
 Safety Endpoints:  
‚Ä¢ Adverse events (type, frequency, intensity , and seriousness)  
‚Ä¢ Clinical chemistry, hematology, urinalysis  
‚Ä¢ Frequency and severity of ovarian hyperstimulation syndrome (OHSS)  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 23 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  3  INVESTIGATIONAL PLAN AND STUDY DESIGN  
3.1 Overall Design and Plan ‚Äì Description  
This multicenter, randomized, double -blind, placebo -controlled study will be performed in 
approximately [ADDRESS_272927], therapy should be conti nued for approximately another 2 weeks to 
maintain corpus luteum  function  (continue until confirmatory serum pregnancy test).  Subjects will 
discontinue treatment either at the onset of menses or after having two (2) negative or two (2) 
positive confirmatory serum pregnancy test s.  Subjects will be required to return to the study site for 
pharmacodynamic blood draws, TVUS, serum pregnancy tests, and safety follow -up assessments.  
The study will consist of 3 periods: Screening (includes progestin ch allenge test), Treatment 
(includes pi[INVESTIGATOR_226936] 14 days and treatment phase), and Follow -up. 
Screening (Day -60 to Day -1): Only subjects with diagnosed primary amenorrhea with HH should 
be screened for this trial.  Only subjects who desire preg nancy will b e eligible to participate in this  
trial. 
The site will obtain written informed consent before any study -related procedures begin.  Upon 
signing the I nformed Consent Form, subjects will be screened based on inclusion/exclusion criteria.  
The ass essments during the screening period will include medical/gynecologic history, safety 
laboratory tests (chemistry, hematology, urinalysis), other laboratory tests (serum pregnancy, LH, 
FSH, E 2, P4, prolactin [PRL], and thyroid -stimulating hormone [TSH] levels), vital signs (blood 
pressure, heart rate, body temperature), Papanicolaou ( PAP ) smear (if not done within the last 
24 months ; PAP smear may be performed at Screening and for every patient if warranted, per 
investigator discretion), TVUS documenting normal uterus and adnexa, and a 
physical/gynecological examination.  A normal or stable computed tomography (CT) scan or 
magnetic resonance imaging (MRI) scan of the hypothalamic pi[INVESTIGATOR_226932].  The male partner should have a documented recent normal 
semen analysis  (within 1 year) .  A progestin challenge test will be initiated to confirm HH.   
Rescreening will be allowed at the investigators‚Äô discretion for s ubjects who exhibit laboratory tests 
outside of the normal or required range.   No subject may be rescreened more than once.  
Rescreening for the progestin challenge test is not allowed.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 24 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272928] :  After confirmed negative serum pregnancy te st, subjects will be 
dispensed 10 mg of medroxyprogesterone acetate (Provera¬Æ)[ADDRESS_272929] dose of progestin will continue to the 
treatment period .  Per i nvestigator‚Äôs discretion, occasional spotting is not considered withdrawal 
bleeding.  Subjects with ute rine bleeding are considered screen failures and will be ineligible for 
study participation.   Rescreening for the progestin challenge test is not allowed.  
Treatment (Day 1 to approximately Day 3 7): Subject who do not have uterine bleeding within 
[ADDRESS_272930] dose of progestin will return to the clinic; a negative urine pregnancy test result 
is required and then the subject will be randomly assigned to 1 of 4 treatment arms: LutrePulse 
OmniPod SC 10 Œºg/pulse, 15 Œºg/pulse, 20 Œºg/pulse , or placebo (10 , 15, and 20 Œºg/pulse delivery 
setting) every 90 minutes.   
Subjects will be instructed on the application of the OmniPod pump (See Instructions for Use 
[IFU]) .11,[ADDRESS_272931] OmniPod pump will be applied on Day 1.  Each OmniPod pump will be wo rn 
for 3 days (Days 1 -3, 4-6, 7-9, etc. to approximately Day 3 7).  The subject will apply subsequent 
OmniPod pumps every 4th day at approximately the same time as the first application  (¬±1 hour) .   
Pharmacodynamic (PD) assessments :  A blood sample for E 2, LH and FSH will be taken on Day  1 
(pretreatment baseline) prior to dosing.  Additional blood samples for only LH and FSH will be 
taken 5, 15, 30, 60, and [ADDRESS_272932] dose is administered.   
A blood sample for E 2, LH and FSH will be taken on Day 10 at the same time as the Day 1 initial 
sample (¬±1 hour) and before the first dose is administered by [CONTACT_48657] [ADDRESS_272933] dose is 
administered.   
Follicular and endometrial development: Follow -up will begin on Day 10 of treatment.  
Follicular and endometrial development will be monitored by [CONTACT_226952]‚Äôs discretion  (minimum of 3 TVUS) , until a dominant follicle of ‚â•  18 mm mean 
diameter and normal endometrium (thickness and pattern) are confirmed.  If a dominant follicle ‚â• 
18 mm mean diameter is not observed after 21 full days of treatment, the therapy will be 
discontinued .  However, the treatment may be continued for a maximum of 3 9 days at the discretion 
of the investigator if the patient has growing follicle(s) .  After Day 10, a single blood sample for E [ADDRESS_272934] who has an 
increased risk of develo pi[INVESTIGATOR_226933]/ OHSS (4 or more follicles with a mean diameter ‚â• 
15 mm by [CONTACT_226960] E 2 levels ‚â• 1200 pg/mL) will be discontinued from treatment.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 25 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  LH surge detection  with Clearblue¬Æ digital ovulation urine test  13 will begin when follicles with a 
mean diameter ‚â• [ADDRESS_272935] ( Appendix II). The subject should notify the site 
immediately once the surge has been detected to schedule a visit within 72 hours  for confirmatory 
TVUS.  Subjects will be advised to engage in sexual intercourse on the day of LH surge, the day 
following LH surge, and per investigator‚Äôs discretion thereafter.  The subject should also document 
the date(s) of sexual intercourse on the subject diary card.  
If LH surge is not detected after [ADDRESS_272936] will be discontinued.  However, 
the treatment may be continued for a maximum of 3 9 days at the discretion of the investigator if the 
patient has growing follicle(s) .  The subject will be instructed to visit the site to return all study drug 
and the OmniPod System.  
Blood samples for progesterone (P 4) levels:  A single blood sample for P 4 will be taken on Day 1 
(pre-treatment baseline) prior to dosing.  Blood samples will also be obtained on Day 19, Day 21, 
Day 23, Day [ADDRESS_272937] discontinued the 
study early and ended treatment on or after Day 14, a blood sample will also be taken at the End-of-
Study Visit .  
Menses Onset:   Subjects who begin menstruating after treatment was initiated  will be instructed to 
stop the treatment and to visit the site to return all study drug and the OmniPod System .  The site 
will record the first day of menses and duration of menses for all non -pregnant subjects.  
Serum pregnancy tests ( ÔÅ¢-hCG):  will be per formed 14 days (+ 4 days) after LH surge and [ADDRESS_272938] will return within 5 days (unscheduled visit) to confirm  
pregnancy with another test.   
After obtaining two (2) negative or two (2) positive confirmed serum pregnancy test result s, the 
treatment will complete.      
All subjects will be assessed for an End -of-Study visit and return all study drug and the OmniPod 
System . 
 
 
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 26 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  Follow -up:  
TVUS for pregnancy outcome:  Subjects who achieve pregnancy (2 positive serum pregnancy tests) 
will be followed up for clinical pregnancy (gestational sac and fetal heart movement) [ADDRESS_272939] data for ongoing pregnancy rate (fetal heart movement at gestational Week 11 or Week 12), 
including safety follow -up of the subjects for miscarriage , fetal anomalies and live birth rate .  
3.2 Number of Centers and Subjects  
The study will be conducted in approximately 50 sites in the [LOCATION_002]  and Canada.  
Approximately 60 fema le subjects will be randomized.  
3.3 Discussion of Study Design and Choice of Control Groups  
This is a multicenter, randomized, double -blind, placebo -controlled  trial.  Subjects with primary 
amenorrhea with HH will be treated with 1 of 3 doses of pulsatile GnRH , or placebo, administered 
SC via the OmniPod  pump manufactured by [CONTACT_45915].  
The three active dose regimens of GnRH and placebo will be administered  using indistinguishable 
vials to maintain the blind .  Insulet  is a leader in wearable insulin pump technology with its 
OmniPod Insulin Management System.  The OmniPod Insulin Management System, a 
revolutionary, discreet and easy -to-use insulin infusion sy stem, features 2 easy -to-use parts with no 
tubing and fully automated cannula insertion.  Insulet worked with Ferring Pharmaceuticals to 
develop a system for the delivery of gonadorelin acetate.  A custom version of the OmniPod's 
Personal Diabetes Manager was developed, which was the first non -diabetes drug delivery 
application for the OmniPod System.  The OmniPod System is expected to be an effective platform 
technology for the delivery of various drugs that require continuous or frequent infusions , includ ing 
GnRH . 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 27 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  4 SELECTION OF STUDY POPULATION  
4.1 Inclusion Criteria  
Subjects who meet all of the following criteria will be eligible for the study:  
1. Signed written informed consent prior to any study -related procedure  
2. Women 18 - 40 years old  
3. Body mass index (BMI) between 18 and 38 kg/m2 
4. Documented clinical history or recently diagnosed with primary amenorrhea with 
hypogonadotropic hypogonadism  
5. Hormonal values in a centrally analyzed fasting blood sample: FSH < 5 IU/L and mean 
LH < 5 IU/L  
6. Desir e to become pregnant  
7. Discontinued estrogen -progesterone replacement therapy at least [ADDRESS_272940] performed during screening  
9. Normal PAP smear within 24 months of the initial visit (PAP smear can be performed at 
Screening, per investigator discretion  and standard of practice  if warranted, even if 
results within 24 months are available)  
10. Normal or stable CT scan or MRI scan of the hypothalamic pi[INVESTIGATOR_226937]  
11. Prolactin and TSH within normal limits for th e clinical laboratory at the S creening Visit 
12. Male partner with normal semen analysis, including volume, liquefaction time, sperm 
count, and motility, according to the local laboratory normal criteria, within the past 
year 
13. Normal TVUS at Screening with resp ect to uterus and adnexa (presence of both ovaries 
and tubes, without evidence of clinically significant abnormality) and with normal 
uterine cavity, normal cervix  
14. Tube patency on saline tubal perfusion, hysterosalpi[INVESTIGATOR_226938] 2 years  
15. Willing and able to comply with the protocol for the duration of the study  
 
 
 
 
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 28 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272941] from study enrollment:  
1. Any medical condition that, in the judgment of the investigator, may interfere with the 
absorption, distribution, metabolism, or excretion of the drug  
2. A history of or currently diagnosed with clinically important cardiovascular, pulmonary 
(e.g., serious corticosteroid -dependent asthma), gastrointestinal, hepatic, metabolic, 
renal, endocrinological (e.g., insulin -dependent diabetes mellitus), or neurologi cal (e.g., 
epi[INVESTIGATOR_002], serious migraine, CNS lesions [in cases where HH is secondary to a CNS 
lesion or its treatment]) abnormality   
3. A history of adrenal or uncontrolled thyroid disorders or hyperprolactinemia  
4. Prior treatment cycles with gonadotropi[INVESTIGATOR_226939] 2 months  
5. Known allergy to study drug or its components  
6. Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis  C 
7. Ovarian enlargement or cyst of unknown etiology  
8. Abnormal gynecological bleeding of undetermined origin  
9. Previous or current hormone -dependent tumor  
10. Known active substance abuse  
11. Planning to undergo in vitro fertilization procedure in the course of a study treatment 
cycle  
12. Currently undergoing treatment with gonadotropin hormones (FSH and LH), 
psychotropic medi cation, sex hormones, or any other medication known to interfere 
with normal reproductive function or that can affect GnRH secretion (e.g., neuroleptics, 
dopamine antagonists, spi[INVESTIGATOR_8407], levodopa, phenothiazine, digoxin)  
13. Ongoing pregnancy or lactation  
14. Participation in any experimental drug study within 30 days prior to screening  
15. Previously randomized in this study  
16. The patient is considered by [CONTACT_941] i nvestigator to be unsuitable to participate in the trial 
for any other reason  
17. The patient has a mental inc apacity or language barrier precluding adequate 
understanding or cooperation .  
 
 
 
 
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 29 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  4.3 Prior and Concomitant Therapi[INVESTIGATOR_226940]/ Pre-treatment  Period until th e completion of the study.   
Details of all concomitant medications (and other therapi[INVESTIGATOR_014]) including the main reason for their 
prescription must be recorded in the medical source data and the electronic case report form ( eCRF ) 
for all eligible patients with in 14 days of the Screening Visit  until the completion of the study .  This 
information should include name [CONTACT_18467], route of administration, indication, and duration of 
treatment. Any changes (including new therapi[INVESTIGATOR_014]) must be recorded at each subsequen t trial visit.  
4.[ADDRESS_272942] has the right to refuse further participation in the study at any time and without 
providing a reason(s).  A subject‚Äôs participation is to terminate immediately upon her request.  The 
investigator should see k to obtain the reason(s) if possible and record this in the eCRF.  
If, at the time of refusal, a dose of the investigational product has already been administered, the 
subject must be advised to agree to follow -up safety investigations, which will include all 
procedures outlined in the End -of-Study Visit. Any early term subjects should complete this visit 
within [ADDRESS_272943] may be withdrawn from the study at any time at the discretion of the investigator; the 
reason should be discussed with the sponsor prior to discontinuing the subject and the reason fully 
documented in the eCRF.  Should the subject, during the cour se of the study, develop conditions 
that would have prevented her entry into the study according to the exclusion criteria, she must be 
withdrawn immediately.   
A subject who has an increased risk of developi[INVESTIGATOR_226933]/ OHSS (4 or more follicles 
with a mean diameter ‚â•  15 mm by [CONTACT_226960] E 2 levels ‚â•  1200 pg/mL) will be discontinued from 
treatment.   
In addition, any clinically important  adverse physical or symptomatic findings /events  and/or 
abnormal laboratory findings  that are above the pre-specifi ed critical values defined in the 
laboratory manual will be grounds for discontinuation  from the study.     
Subjects who do not become pregnant following treatment (2 negative serum pregnancy tests) will 
be discontinued from the study  and must complete an End-of-Study Visit  on the day of the second 
negative serum pregnancy test . 
4.[ADDRESS_272944] Replacement  
Subjects discontinued from the study will not be replaced.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 30 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272945] (IMP)  
Subject s will be randomly assigned to 1 of 4 treatment arms:  
‚Ä¢ LutrePulse OmniPod SC 10 Œºg/pulse as a fixed dose (Test Product)  
‚Ä¢ LutrePulse OmniPod SC 1 5 Œºg/pulse as a fixed dose  (Test Product)  
‚Ä¢ LutrePulse OmniPod SC 20 Œºg /pulse as a fixed dose  (Test Product)  
‚Ä¢ Placebo  (10, 15, or 20 Œºg/pulse as a fixed ‚Äúdose‚Äù)    
Subjects will receive consecutive pulses of GnRH or placebo, each delivered at 90 -minute intervals, 
for approximately  37 days of treatment.  Each OmniPod will be worn for 3 full days (Days 1 -3, 4-6, 
7-9, etc. to approximately Day 3 7) and will be replaced every 4th day (i.e., Day 4, Day 7, Day 10, 
etc.).  New OmniPod pumps should be applied at approximately the same time as the first pump  
(¬±1 hour) . 
Test Product - LutrePulse (gonadorelin acetate)  
LutrePulse is a white lyophilized powder that is highly soluble in water and is intended for SC 
pulsatile injection with the OmniPod pump after reconstitution.  LutrePulse is manufactured by [CONTACT_103].  Each vial with 13.2 mg powder contains 3.2 mg of lyophilized gona dorelin acetate, 
equivalent to 2.91 mg gonadorelin; each vial with 10 mL solvent (pH 4.0 ‚Äì 5.0) contains sodium 
chloride, water for injection, and hydrochloric acid 10%.  Randomized fixed doses of either [ADDRESS_272946] ‚Äì Placebo   
The placebo product is a  vial with solvent (pH 4.0 ‚Äì 5.0) containing sodium chloride, water for 
injection, and hydrochloric acid 10%.  Placebo is manufactured by [CONTACT_456].  Each vial of 
placebo will appear similar to the LutrePulse 3.[ADDRESS_272947].  Placebo doses will be the same amount of volume respectively , either 10 , 
15 Œºg, or 20 Œºg/pulse,  as the Lutre Pulse OmniPod dose without active drug substance.   
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 31 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  Drug Delivery System  
The OmniPod Drug Delivery system is a disposable delivery pump (OmniPod) with a handheld 
wireless controller (the Manager) for SC drug delivery (see  Figure 1).  The OmniPod is a discreet 
and easy -to-use delivery pump featuring two parts, with no tubing and fully automated cannula 
insertion manufactured by [CONTACT_226961] (locat ed at [ADDRESS_272948], MA, US).  A 
custom version of the originally developed OmniPod's Manager (wireless controller for insulin 
delivery) was subsequently modified for use with LutrePulse.  
The OmniPod is a small (1.530‚Äù wide √ó 2.055‚Äù long √ó 0.575‚Äù  high), lightweight (<  1.1 oz.), self -
adhesive device filled with LutrePulse or placebo and worn directly on the body.  The OmniPod 
delivers precise doses of LutrePulse or placebo through a small flexible subcutaneous cannula, 
based on instructions program med into its wireless controller, the Drug Delivery Manager.  The 
deliverable reservoir volume is 2000 ŒºL.  The cannula insertion depth is between 6  and 7 mm at 
‚â§ 50¬∞ insertion angle when measured from the perpendicular axis to the skin, and the cannula is  
inserted only once with each OmniPod.  
The OmniPod‚Äôs adhesive keeps it securely in place for up to 3 days.  Body lotion, creams, or oils 
should not be used near the infusion site, as these products may loosen the adhesive.  The infusion 
site should be chan ged each time a new OmniPod is applied; the new site should be at least [ADDRESS_272949]‚Äôs 
LutrePulse or placebo delivery instructions and wirelessly monitors the OmniPod‚Äôs operation.  The 
Manager is 2.5‚Äù wide √ó 4.5‚Äù long √ó 1.0‚Äù high, and it weighs 4.[ADDRESS_272950] keepi[INVESTIGATOR_007], and automated cannula insertion.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 32 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL   
      
The OmniPod is applied to the skin with an 
adhesive backing, similar to an adhesive bandage.          The Manager  
Figure 1: The OmniPod Drug Delivery System  
 
More detailed characteristics of the investigational product, dosage and administration can be found 
in the Investigator‚Äôs Brochure.14  An abbreviated version of the LutrePulse User Guide  for the 
OmniPod  Pump9 is provided in the LutrePulse ‚Ñ¢ Healthcare Professional (HCP) Quick Reference 
Guide and LutrePulse ‚Ñ¢ Guide for the Patient .11, [ADDRESS_272951]  (NIMP)  
During the progestin challenge, subjects will be dispensed  10 mg medroxyprogesterone acetate 
(Provera¬Æ) for oral administration, a derivative of progesterone used to induce menstrual onset.  
Provera 10 mg tablets will be dispensed via prescription in the US .  For Canada, Provera will be  
provided by [CONTACT_226962] 5  mg (ÔÇ¥2) tablets or 10 mg tablets.   
More detailed characteristics can be found in the package insert for medroxyprogesterone acetate .10  
5.2 Packaging and Labeling  
Packaging and labelling of the medicinal products will be performed under the responsibility of the 
IMP Department at Ferring Pharmaceuticals A/S in accordance with GMP and national regulatory 
requirements.   

Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 33 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272952] kits on Treatment Day 1,  
Treatment Day 10, and Treatment Day 2 5 (if applicable).  Subjects will receive a sharps container 
for safe disposal of nee dles.  The OmniPod Managers will also be supplied to the subjects on 
Treatment Day  1.   
The active and placebo study drug will be identical in appearance and labeling.  The IMP will be 
packaged and distributed using a secure system assuring full traceabili ty from production to site.  
The unblinded coordinator will program the Manager to deliver the assigned dose, according to the 
randomization schedule  (but will remain blinded to assigned study drug, whether active or placebo) .  
Each subject study kit will contain the following:  
‚Ä¢ OmniPod Manager  (initial shipment only)  
‚Ä¢ Replacement batteries for Manager  (initial shipment only)  
‚Ä¢ OmniPod pump(s) (2  mL syringe and needle included)  
‚Ä¢ Vial adapter(s)  
‚Ä¢ Vial(s) of LutrePulse or Placebo  
‚Ä¢ One (1) sharps container  
‚Ä¢ Alcohol swab(s)  
Each subject study kit will have a study specific  label uniquely numbered assuring traceability with 
one self -adhesive tear -off portion to be affixed to the source document form and maintained at the 
trial site.   
5.2.[ADDRESS_272953] 
Provera¬Æ will have a study specific label uniquely numbered assuring traceability.  No modi fication 
will be made from the  usual commercial state,  other than application of trial specific labelling .  
5.[ADDRESS_272954]  is stored in appropriate conditions in a reasonably secure, substantially 
constructed locked cabinet with controlled access.  The temperature in the storage compa rtment 
shall be constantly monitored with a minimum/maximum thermometer and the values shall be 
controlled regularly and documented.  Deviations in storage temperature must be reported to the 
sponsor without delay  and t he IMP cannot be used until acceptanc e from the sponsor is received.  
The investigator or designee will also ensure the subject has an understanding of the proper storage 
conditions for IMP at home.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 34 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  All LutrePulse products and supplies (including unopened pumps) should be stored in a cool, dry 
place.  Medication vials should not be stored above 25¬∞C (77¬∞F). The OmniPod‚Äôs operating 
temperature is 5 -40¬∞C (40 -104¬∞F).  Extreme heat or cold can damage the OmniPod and the 
Manager, causing them to malfunction.  The OmniPod should not be exposed to direct sunlight for 
long periods of time and should be removed prior to using hot tubs, whirlpools, or saunas.  The 
Manager should not be left inside a car or other places where it could be exposed to extreme 
temperatures.  If Pods are exposed to extreme t emperatures, they should first be returned to room 
temperature and inspected carefully before they are used.  During storage, the batteries should 
remain in the Manager.  See the User Manual for details regarding OmniPod pump use and storage.9 
Provera¬Æ should be stored  according to the commercial pack.  
The investigator or designee will dispense the medication only to the identified subjects of this 
study, following the procedures described in this study protocol and documented in the subject 
dispensing log.  Drug inventory/dispensing will be documented in the source documents for each 
subject and the drug accountability binder.  Subjects will be give n a diary card on Treatment Day [ADDRESS_272955]  will be returned to the 
sponsor.  
5.4 Blinding / Unblinding  
5.4.1 Blinding  
To ensure blinding, subjects assigned to placebo will be randomized to 1 of 3 placebo ‚Äúdose‚Äù 
groups ‚Äì 10 ÔÅ≠g, 15 ÔÅ≠g, or 20 ÔÅ≠g according to a computer -generated randomization list prepared for 
all trial sites.  Study personnel involved in the conduct of the study will be blinded to the assigned 
drug product (active or placebo) regardless of dose.  The OmniPod Manager will displa y the dose 
once it has been programmed for a subject, regardless of active or placebo assignment.  
All eligible subjects will be randomly assigned at least 5 days before Treatment Day 1  (7 days for 
sites in Canada) , based on the computer -generated randomiza tion list.  The first 15 eligible subjects 
will be randomly assigned to 1 of 3 treatment arms: LutrePulse OmniPod SC 10 ÔÅ≠g, LutrePulse 
OmniPod SC 20 Œºg, or OmniPod SC placebo in a 1:1:1 ratio.  The subsequent 25 eligible subjects 
will be randomly assigned to LutrePulse OmniPod SC 10 ÔÅ≠g, LutrePulse OmniPod SC 15 ÔÅ≠g, 
LutrePulse OmniPod SC 20 Œºg, or OmniPod SC placebo in a 1:2:1:[ADDRESS_272956] of the eligible 
subjects will be randomly assigned to LutrePulse OmniPod SC 10 ÔÅ≠g, LutrePulse OmniPod SC 15 
ÔÅ≠g, Lu trePulse OmniPod SC 20 Œºg, or OmniPod SC placebo in a 1:1:1:[ADDRESS_272957] , the placebo 
subjects will be randomly assigned to the equivalent dosing setting in the Manag er for 10 ÔÅ≠g /pulse 
or 20 Œºg /pulse  for the first 15 eligible subjects and 10 ÔÅ≠g /pulse, 15  ÔÅ≠g /pulse, or 20 Œºg /pulse for 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 35 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  the other randomization schemes.   The randomization dose assignment (dose only) will be available 
to the OmniPod Manager programmer ( unblinded coordinator), but not to any other site personnel 
involved in the conduct and evaluation of the study until the study database is declared clean and is 
released to the statistician.   
Prior to the start of the study, the investigator will assig n a coordinator to act as the unblinded 
coordinator.  This person will be the only person unblinded to the subject‚Äôs study drug dose and will 
be responsible for the set -up of the Manager, distribution and accountability of the drug.  Although 
the unblinded c oordinator will be aware of the dose assigned, the unblinded coordinator will not be 
aware of whether the subject is receiving active drug or placebo.  The unblinded coordinator will 
instruct each subject as to the proper administration and the timing of a dministration of the study 
drug.  This person will be available to answer the subject‚Äôs questions regarding study drug and its 
administration.  
The integrity of the blind will be further preserved by r equiring each subject and the unblinded 
coordinator to s ign a nondisclosure affidavit form ( Appendix I) instructing subjects and the 
unblinded coordinator not to disclose the study drug dosage.  
5.4.[ADDRESS_272958] Treatment  
An emergency decoding possibility  (either a code envelope or another system) will be available to 
the investigator and designated persons at Ferring.  Breaking of the blind for individual subjects in 
emergency situations is only permitted in case of an important adverse event where the kn owledge 
of the IMP in question is required for therapeutic decisions for the management of the subject.  
As far as the emergency permits, the need to break the blind will be agreed by [CONTACT_2183].  The person who opens a code envelope must record on it the reason and the date of 
opening, and then sign and date the opened envelope if a code envelope is prepared.  If the 
randomization is done via an electronic system , the system will record the access for this 
unblinding. It should be recorded  in the eCRF that the code is broken, why, when , and by [CONTACT_20898].  
The investigator must record the event of unblinding in the subject‚Äôs medical record, including the 
reason for unblinding, but not the treatment allocation if this can be avoided.  
In case of ac cidental unblinding to the dose (e.g. , the subject tells the investigator), the same 
documentation as for emergency unblinding must be obtained, i.e. , why, when and by [CONTACT_226963], and the event must also be recorded in the subject‚Äôs med ical record.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 36 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272959]‚Äôs treatment for the purposes of expedited 
reporting to the authorities and/or IECs/IRBs.  In that situation, every effort will be made to 
maintain blinding of sponsor personnel involved in d ata analysis and interpretation.  
Pharmacovigilance/Safety personnel may be unblinded for purposes of reporting suspected 
unexpected serious adverse reactions  (S[LOCATION_003]Rs ).  Regulatory Affairs personnel submit S[LOCATION_003]Rs to 
the FDA.  A US Regulatory Affairs person  not involved with the conduct of the study will be 
designated to submit S[LOCATION_003]Rs to the IND.  
Information on whether the blind has been broken for any subjects must be collected before the 
database is declared clean and is released to the statistician.  
5.5 Selec tion of Doses in the Study  
The selected GnRH dose per pulse will be either 10 Œºg , 15 ÔÅ≠g, or 20 Œºg  delivered at 90 -minute 
intervals.   
The SC GnRH doses proposed in this study are based on existing Ferring data and previously 
published research. The 20 Œºg d ose has been used successfully in clinical studies in the US and 
Europe.3   
In a pharmacokinetic study conducted in a small group of women with hypothalamic amenorrhea, 
SC GnRH administration resulted in pulsatile plasma GnRH and gonadotropin responses 
resembling t hose seen after IV GnRH.15  No significant differences were found between peak LH 
responses to 10  ¬µg/pulse of IV and SC doses of GnRH administered  at 90-minute intervals.   
In Ferring Study 2005 -06, the SC route was associated with a slightly lower rise to peak and a 
slower disappearance of GnRH from the circulation; however, SC and IV dosing produced similar 
peak concentrations and total exposures (area under the  concentration -time curve, AUC).5  The 
study showed 25% bioavailability with SC compared to IV administration of GnRH.  Thus, if the 
most commonly used initiating dose of the IV route is 5 ¬µg /pulse, the SC dose needed to achieve 
approximately the same blood concentration GnRH levels is e xpected to be 4 -fold higher, namely, 
20 ¬µg /pulse.  
Ferring Study 000010 demonstrated favorable GnRH and LH profiles following SC administration 
of 20 ¬µg/pulse doses every 90 minutes of LutrePulse with the OmniPod device.7  Martin (1990) 
reported that [ADDRESS_272960] based on the GnRH pulse frequency in normal 
women.  The literature to date supports a follicular -phase pulse frequency of 90  minutes or less to 
achieve maximum spontaneous ovulation ra tes. 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 37 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272961] Diary Cards  
(Appendix II) documenting date and time of replacement pods will also be monitored. Any unused 
investigational product and Non -Investigational Medicinal products will be accounted for and 
returned to the sponsor.  The used vials, pumps, and Managers  must be returned to the trial site by 
[CONTACT_226964]/or returned to the sponsor.  
5.6.2 Assessment of Compliance  
The OmniPod will be applied at the study site on Treatment Day 1 , Treatment Day 10 , and 
Treatment Day 25  (if applicable) .  All other OmniPods can be applied by [CONTACT_226965].  Subjects will be provided training and an instruction manual .   
On Day [ADDRESS_272962] kits.   These  kits will be distributed to 
the sites together with the IMP for Treatment Days 1 , 10, and 2 5 (if applicable) .   
5.[ADDRESS_272963] and will be 
destroy ed at the site  and/or returned to the sponsor .  Used syringes and needles must be discarded in 
the sharps container and returned to the site.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 38 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  The trial medication delegate at the site should ensure that the destruction of used medicinal 
products is done i n accordance with local legislation/national requirements after the drug 
accountability has been finalized, verified by [CONTACT_2037], and signed off by [CONTACT_170270].  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 39 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  6 STUDY FLOW CHART AND STUDY PROCEDURES  
6.1 Schedule of Activities  
The schedule o f activities for the study is presented in Table 1. 
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 40 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  Table 1 Schedule of Activities  
Procedure  Screening  
(Day -60 
to Day -1) Treatment 
Day 1  Treatment 
Day 10  Follicle 
‚â• 18 mm and 
LH surge  Days 19, 21, 23, 25 and 27  14 (+4) days post 
LH surge and 
[ADDRESS_272964]  E nd-of-
Study 
Visit  
Informed consent  X        
Inclusion/exclusion  X        
Medical/gynecologic 
history  X        
Physical examination  X       X 
Gynecological exam  X       X 
Vital signs  X       X 
Safety laboratory tests  X       X 
Hepatitis B, C, & HIV 
screen  X        
Hormones: PRL, TSH  X        
TVUS  X  X   ‚Äì   Xa   Xb  
Semen analysis  X        
Progestin challenge testc X        
Serum pregnancy test  X     X   
Concomitant medications  X X X X X X X X 
Urine pregnancy test   X      Xd 
Blood samples for E 2 X X Xa Xa     
Hormones: LH, FSH  X Xe Xe      
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 41 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  Procedure  Screening  
(Day -60 
to Day -1) Treatment 
Day 1  Treatment 
Day 10  Follicle 
‚â• 18 mm and 
LH surge  Days 19, 21, 23, 25 and 27  14 (+4) days post 
LH surge and 
[ADDRESS_272965]  E nd-of-
Study 
Visit  
Blood samples for P 4 X X   X   Xf 
Randomization   Xg       
OmniPod applicationh  X       
Clearblue testingi    X      
Begin sexual intercoursej    X     
Adverse events   X X X X X X X 
Follow -up phone callk        X 
a. Follicular size will be monitored every other day (minimum of  3 times) starting at Day 10 until a f ollicle ‚â• [ADDRESS_272966] should be perf ormed at the End -of-Study visit f or all except those with documented f etal heart movement.  
e. On Day 1 ( pre-treatment  baseline) and Day 10 ( post-treatment ), LH and FSH samples will be collected at 0 hour (f irst sample taken prior to dosing) and 5, 15, 30, 60, and [ADDRESS_272967] 5 days bef ore Treatment Day 1  (7 days f or sites in Canada) . 
h. The f irst OmniPod applied will remain on the subject until Day 4, when the second OmniPod will be applied at approximately th e same time  (¬±1 hour) ; each OmniPod will be worn f or 3 f ull days.  
i. When f ollicles ‚â• [ADDRESS_272968] result occurs.   
j. Intercourse to begin at conf irmed Clearblue LH surge.  
k. For subjects who achieve biochemical pregnancy ‚Äì collect ongoing pregnancy rate and birth data.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 42 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  6.2 Study Procedures  
6.2.1 Screening/Pre -treatment  
Screening procedures are to be performed b etween Days -60 and -1.  Note: The diagnosis of 
primary amenorrhea with HH should be known by [CONTACT_093].  
Screening (Days -60 to -1) 
At the Screening Visit, the subject should receive a detailed explanation of the study and , after 
having sufficient time to consider her participation in the study, sign the Informed Consent Form.  
After the subject has signed the Informed Consent Form, the following will be collected/performed:  
‚Ä¢ Inclusion/exclusion criteria  
‚Ä¢ Medical/gynecologic h istory and demographic data  
‚Ä¢ Physical examination, including height and weight  
‚Ä¢ Vital signs (blood pressure, heart rate, and oral temperature)  
‚Ä¢ Clinical safety laboratory assessment:  chemistry, hematology, urinalysis  
‚Ä¢ Other laboratory assessment: hepatitis B , hepatitis C, HIV screen  
‚Ä¢ Hormone assessments:  E2, P4, FSH, LH, prolactin , and TSH  
‚Ä¢ Serum pregnancy test  
‚Ä¢ Gynecological examination (including breast exam) and  Pap smear (unless Pap smear 
results within the past 24  months are provided)  
‚Ä¢ TVUS  
‚Ä¢ Documentation o f normal semen analysis within past year for male partners  
‚Ä¢ Prior/concomitant medication use up to 14 days prior to  the Screening Visit  
‚Ä¢ Progestin Challenge Test  during Screening : 
‚ñ™ Medroxyprogesterone acetate 10 mg oral tablet once daily for 10 days  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 43 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚ñ™ If uterine bleeding occurs within [ADDRESS_272969] is not allowed.  Per investigator‚Äôs discretion, occasion al spotting 
is not considered withdrawal bleeding.  
‚ñ™ If uterine bleeding does not occur [ADDRESS_272970] 5 days before Treatment Day 1  (7 days for sites in Canada) . 
Treatment Day 1  
‚Ä¢ Urine pregnancy test  
‚Ä¢ Blood samples for baseline E [ADDRESS_272971] dose is administered.   
‚Ä¢ Instruction and application of OmniPod  
‚Ä¢ Distribution of LutrePulse subject study kit and Subject Diary Card   
‚Ä¢ Concomitant medication use  
‚Ä¢ Adverse event  and unanticipated adverse device effect  (UADE)  assessment post treatment  
‚Ä¢ 12-lead electrocardiogram (ECG) (for subjects who report chest pain or are symptomatic of 
chest pain)   
Treatment Day 10  
Subjects will return to the study site at approximately the same time as Day 1 for pharmacodynamic 
(PD) assessments and monitoring of follicular development and endometrial thickness.  They will 
remove their current pod and apply their Day 10 pod at the study site.   
‚Ä¢ Concomitant medication use  
‚Ä¢ A single blood sample for E 2  
‚Ä¢ Blood samples for LH and FSH collected  at the same time as Day [ADDRESS_272972] sample (¬± 1 hour), 
before the first dose is administered by [CONTACT_48657] 10 pod and 5, 15, 30, 60, and 90  minutes 
after the dose is administered.   
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 44 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ TVUS to monitor size and number of follicles and endometrial thickness  
‚Ä¢ Adverse e vent and unanticipated adverse device effect assessment  
‚Ä¢ 12-lead ECG (for subjects who report chest pain or are symptomatic of chest pain)  
OmniPod Application Days  
Subjects remove the OmniPod and apply a new OmniPod at approximately the same time as the 
first OmniPod was applied (¬±1 hour)  every fourth day.   This occurs on Treatment Days 4, 7, 10, 13, 
16, 19, and onwards if deemed necessary by [CONTACT_093] . 
After confirmed LH surge , treatment will continue for approximately another 2 weeks to maintain 
corpus luteum  function (continue until confirmatory serum pregnancy test) .   
6.2.3 Treatment Day 11 until LH Surge  
Subjects will return to the study site every other day (o r at the investigator‚Äôs discretion  [minimum of 
3 times ]) to monitor follicular development and endometrial thickness, until a dominant follicle of ‚â• 
[ADDRESS_272973] will be discontinued.  However, the treatment may be continued for a 
maximum of 3 9 days at the discretion of the investigator if the patient has growing follicle(s).  
‚Ä¢ TVUS  
‚Ä¢ Blood collection for E 2 (each time TVUS is performed)  
‚Ä¢ When follicles ‚â• [ADDRESS_272974] should notify the site immediately to 
schedule a visit within 72 hours for confirmatory TVUS and will be advised to 
engage in sexual intercourse on the day of LH surge , the day following LH surge , 
and per investigator‚Äôs discretion thereaf ter   
o Subjects should document the date of their first Clearblue test and the date of their 
first positive test result  on the subject diary card ( Appendix II) 
o  The subject should also document the date(s) of sexual intercourse on the subject 
diary card.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 45 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ Concomitant medication use  
‚Ä¢ Adverse event and unanticipated adverse device effect assessment  
‚Ä¢ 12-lead ECG (for subjects who report chest pain or are symptomatic of chest pain)  
Up to 72 hours  after LH surge  
‚Ä¢ Confirmatory TVUS  
‚Ä¢ Concomitant medication use  
‚Ä¢ Adverse event and unanticipated adverse device effect assessment  
‚Ä¢ 12-lead ECG (for subjects who re port chest pain or are symptomatic of chest pain ) 
6.2.4 Progesterone and Pregnancy Monitoring  
Treatment Days 19, 21, 23, 25 , and 27  
‚Ä¢ Blood collection for P 4  
‚Ä¢ Concomitant medication use  
‚Ä¢ Adverse event  and unanticipated adverse device effect  assessment  
‚Ä¢ 12-lead ECG (for subjects who report chest pain or are symptomatic of chest pain ) 
‚Ä¢ LutrePulse Omnipod t reatment continues for luteal phase support for subjects with 
confirmed LH surge  
Interview and study drug return  
Non-pregnant subjects will visit the site to return u sed and unused study drug product, their subject 
diary card and the OmniPod delivery system and report the day menstruation began and duration of 
menses, if applicable.   Gonadotropin s for one treatment  cycle  as well as compensation toward a 
future IVF cycle  could be offered to all non -pregnant subjects  who participated in and completed 
the study  (had at least 14 days of study medication)  and completed an End -of-Study  visit.  No 
study -related follow -up will be  conducted  regarding such cycles . 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 46 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  14 (+ 4) days after LH surge and 3 days thereafter  
Two positive serum pregnancy tests are required to confirm biochemical pregnancy 14 ( + 4) days 
after LH surge and [ADDRESS_272975] will return 
within 5 days (unscheduled visit) to confirm pregnancy with another serum pregnancy test.  
Subjects with [ADDRESS_272976] . 
‚Ä¢ Serum pregnancy test  
‚Ä¢ Concomitant medication use  
‚Ä¢ Adverse event and unanticipated adverse device effect assessment  
‚Ä¢ 12-lead ECG (for subjects who report chest pain or are symptomatic of chest pain ) 
[ADDRESS_272977]  
‚Ä¢ TVUS to detect gestational sac and fetal heartbeat  
‚Ä¢ If fetal heartbeat is not documented, the subject may return within 7 days for another TVUS  
‚Ä¢ Concomitant medication use  
‚Ä¢ Adverse event and unanticipated adverse device effect assessment  
‚Ä¢ 12-lead ECG (for subjects wh o report chest pain or are symptomatic of chest pain ) 
End-of-Study Visit  
The End -of-Study Visit is performed in conjunction with the final TVUS visit  [ADDRESS_272978] for 
subjects who do not become pregnant (2 negative serum pregnancy tests).  
‚Ä¢ Gynecological examination , including breast exam  
‚Ä¢ Physical examination, including weight  
‚Ä¢ Vital signs (blood pressure, heart rate, and oral temperature)  
‚Ä¢ 12-lead ECG (for subjects who report chest pain or are symptomatic of chest pain)   
‚Ä¢ Clinical  safety laboratory assessment: chemistry, hematology, urinalysis  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 47 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ Urine pregnancy test ( for all except those with documented fetal heart movement ) 
‚Ä¢ Blood collection f or P 4 (only for subjects who have discontinued the study and ended 
treatment on or after Day 14 ) 
‚Ä¢ Concomitant medication use  
‚Ä¢ Adverse event and unanticipated adverse device effect assessment  
After the End -of-Study V isit, the site will be asked to provide follow -up information on subjects 
with a biochemical pregnancy regarding ongoing pregnancy rate and birth data.  The follow up will 
be conducted via telephone or mail.  The site will also document miscarriage/pregnancy lo ss 
(spontaneous and/or induced), date of live birth, number of deliveries, fetal anomalies , and birth 
defects.    
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 48 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272979] chemiluminometric technology 
(ICMA).  Estradiol, progesterone and FSH will also be assayed by a central laboratory service.  
A blood sample for E 2, LH and FSH will be taken on Day 1 (pre -treatment baseline) prior to dosing.  
Additional blood samples for LH and FSH will be taken 5, 15, 30, 60, and [ADDRESS_272980] 
sample (¬± 1 hour) before the first dose is administered by [CONTACT_48657] [ADDRESS_272981] has a 
TVUS to monitor follicular development and endometrial thickness.  
PD blood samples of 10 mL (for LH, FSH, and E 2 levels) will be collected.  
Serum samples will be obtained  following centrifugation of clotted samples.  All serum samples 
should be clearly labeled before freezing to ensure label adherence to the container and to avoid 
sample mix up.  
All samples will be kept frozen at -20ÔÇ∞C and shipped on dry ice.  No more than  [ADDRESS_272982]‚Äôs number and 
initials, actual 24 -hour clock and date time of each sample collection, sample identification number, 
and other appropriate information will be r ecorded on the label and in the eCRF.  Any deviations 
either from the scheduled time of sample collection or from the instructions for handling and 
processing of samples should be documented in the study records.  
Specific instructions for blood collection will be provided in a laboratory manual to the study 
center.  
7.2 Transvaginal Ultrasound  
A transvaginal ultrasound, including ovaries, uterus, endometrium, and adnexa, will be performed 
at Screening (to determine eligibility) and beginning at Day 10 of treatme nt to monitor number and 
size of follicles and endometrial thickness.  Subjects will return every other day (or based on 
investigator judgment) for additional TVUS  (at least 3 TVUS are to be performed) . For subjects that 
become pregnant, a TVUS will be per formed [ADDRESS_272983]. 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 49 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  7.3 Detection of LH Surge  
When follicles ‚â• [ADDRESS_272984] result occur s, subjects are to notify the site 
and will be advised to engage in sexual intercourse on the day of LH surge , the day following LH 
surge , and per investigator‚Äôs discretion thereafter.  
7.4 Progesterone Evaluations  
Blood samples (10 mL) for measurement of proge sterone levels will be obtained by [CONTACT_226966] 19, 21, 23, [ADDRESS_272985] that discontinues the study early and ends treatment on or after Day 14.  A P4 level ‚â• 6 
ng/mL as measured by a central laboratory  indicates ovulation.  
7.5 Pregnancy Assessments  
7.5.1 Serum Pregnancy Tests  
Serum pregnancy tests ( ÔÅ¢-hCG) will be performed at Screening , and negative pregnancy test results 
are required for study admission and/or administration of pulsatile GnRH (urine pregnancy tests are 
performed prior to initial study drug administration  for all subjects and at the End -of-Study visit for 
all subjects except those with documented fetal heart movement ).  To confirm biochemical 
pregnancy, a serum pregnancy test will be performed 14 days ( + 4 days) after LH surge and [ADDRESS_272986] will return within 5 days (unscheduled visit) to 
confirm pregnancy with another test.  Subjects who have [ADDRESS_272987].  
7.5.2 Pregnancy and Pregnancy Outcome  
Subjects who achieve pregnancy (2 positive serum pregnancy tests) will be followed up for clinical 
pregnancy (gestational sac and fetal heart movement) and will complete their final visit (End-of-
Study Visit) on the day of documented fetal heart movement on TVUS ([ADDRESS_272988]).  
7.6 Safety Assessments  
7.6.1 Medical History  
A complete medical/gynecologic history will be obtained at Screening and will include a review of 
prior medical history and female reproductive status.  Documentation of the diagnosis of primary 
amenorrhea with HH should be provided, including normal or unchanged CT scan or MRI scan of 
the hypothalamic pi[INVESTIGATOR_226941] < 5 IU/L and LH 
< 5 IU/L.  Medical history findings will be recorded in the eCRF.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 50 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272989] exam will be performed at 
Screening.  In addition, a Pap smear (or other cervical cancer screening) will also be performed at 
Screening if not done in the previous 24 months (PAP smear can be performed at Screening, per 
investigator discretion, even if results within 24 months are available).  If done in the previous 
[ADDRESS_272990]‚Äôs chart.  At the End -of-
Study Visit (or at the time of early termination), another phy sical and gynecological examination 
including vital signs will be performed.  Any clinically significant deterioration from baseline will 
be recorded as an adverse event.  
7.6.[ADDRESS_272991] pain or symptoms occur.  
7.6.5 Clinical Laboratory Tests  
[IP_ADDRESS]  Hematology, Serum Chemistry, and Urinalysis  
A standard panel , as well as the following safety laboratory tests, will be performed at Screening 
and at the End -of-Study Visit (or at the time of early termination).  A [ADDRESS_272992] is 
required prior to collecting the blood samples.  The total amount of blood required for safety 
assessments is approximately 80 mL. 
Hematology : red blood cell count, white blood cell count, hematocrit, hemoglobin, platelet count, 
and differential count.  
Serum Chemistry : fasting glucose, blood urea nitrogen, creatinine, potassium, sodium, chloride, 
calcium, total protein, albumin, t otal bilirubin, alkaline phosphatase, aspartate aminotransferase, 
alanine aminotransferase, and gamma glutamyl transferase.  
Urinalysis : leukocyte esterase, blood, pH, specific gravity, protein, glucose, urobilinogen, and 
microscopic if positive for blood o r protein.  
[IP_ADDRESS]  Serological Testing  
Serological testing for hepatitis B, hepatitis C, and HIV I and II will be performed at Screening.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 51 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  [IP_ADDRESS]  Hormone Testing  
Prolactin ( PRL) and  TSH will be measured only at Screening.  P [ADDRESS_272993] that discontinues the study early and ends treatment on or after Day 
14.  E 2 levels will be measured at Screening , Treatment Days 1  and 10 , and each time a TVUS is 
performed.  LH and FSH levels will be measured at Screening and again on Treatment Days 1  and 
10 (prior to first dose and 5, 15, 30, [ADDRESS_272994] dose is administered).   
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 52 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  7.6.6 Ovarian Hyperstimulation Syndrome Monitoring  
In women undergoing controlled ovarian hyperstimulation, an excessive response to follicular 
stimulating agents may lead to the development of ovarian hyperstimulation syndrome (OHSS).  
OHSS represents a spectrum that can be categorized as mild, moderate o r severe.   
The following table will be used in assessing and classifying the severity of OHSS . 
Table 2 Classification of Mild, Moderate and Severe OHSS17 
Mild OHSS  
     Grade 1  Abdominal distension and discomfort  
     Grade 2  Features of grade 1 plus nausea/vomiting and/or diarrhea. Ovaries enlarged to 
5-12 cm.a) 
Moderate OHSS  
     Grade 3  Features of mild OHSS plus ultrasonic evidence of ascites.b) 
Severe OHSS  
     Grade 4  Features of moderate OHSS plus clinical evidence of ascites and/or hydrothorax 
(or breathing difficulties). Paracentesis due to OHSS symptoms. c) 
     Grade 5  All of the above plus change in blood volume, inc reased blood viscosity due to 
hemoconcentration, coagulation abnormalities, and diminished renal perfusion and 
function.d)  Hospi[INVESTIGATOR_226942].  
a) For each ovary, the size will be the average of the greatest diameter and its greatest perpendicular diameter. Ovarian 
enlargement will be based on the average size of the right and left ovaries. The sizes of both ovaries should be 
recorded.  
b) For subjects with transvaginal evidence of ascites, the size of the fluid pockets in the pelvis (Douglas pouch, vesico -
uterine pouch, etc.) should be estimated by [CONTACT_2206], 
and multiplying these two numbers (the unit will be cm2). Peritoneal fluid is the total size o f all fluid pockets in the 
pelvis.  
c) In case of paracentesis, the volume of fluid drained should be measured.  
d) Hemoconcentration is defined as hematocrit >45 %. Electrolyte disturbances is defined as hyponatremia (sodium 
<135 mEq/L) and/or hyperkalemia (pota ssium >5.0 mEq/L). Coagulation abnormalities are defined as presence of 
thromboembolic events, abnormal prothrombin time or abnormal activated partial thrombin time. Diminished renal 
perfusion is defined as creatinine >1.2 mg/dl. Oliguria is defined as uri ne output less than 500  mL / [ADDRESS_272995] and on the Adverse Event page in the eCRF.  Severe OHSS that requires medical or 
surgical intervention (i.e., paracentesis, hospi[INVESTIGATOR_059], dopamine administration) is considered a 
serious adverse event (see Section  8.3). 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 53 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272996] visit.  Any use of prior medicatio n or concomitant medication, including vitamin or 
dietary supplements or oral herbal preparations, will be recorded in the source documents and the 
eCRF and incl ude the following information: name [CONTACT_2100], total daily dose, route of 
administration, s tart and stop dates, and reason for use.  If the reason for the use of concomitant 
medication meets the definition of an adverse event, the adverse event should be recorded in the 
source documents for that subject and on the Adverse Event page of the eCRF.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 54 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272997] participating in a clinical trial.  It 
includes:  
‚Ä¢ Any unfavorable and unintended sign, symptom or disease temp orally associated with the 
use of the IMP, whether or not considered to be caused by [CONTACT_2203].  
‚Ä¢ Adverse events commonly observed and adverse events anticipated based on the 
pharmacological effect of the IMP.  
‚Ä¢ Any laboratory abnormality, vital sign or finding from physical or gynecological  
examination assessed as clinically significant by [CONTACT_093]  [note: findings from 
assessments and examinations done during screening are not adverse events, but are 
recorded as medical history.]  
‚Ä¢ Accidental injuries, rea sons for any change in medication (drug and/or dose), reasons for 
any medical, nursing or pharmacy consultation, or reasons for admission to hospi[INVESTIGATOR_226943].  
‚Ä¢ Overdoses and medication errors with and without clinical consequences.  
8.[ADDRESS_272998] visit.  
The sources of adverse events cover:  
‚Ä¢ The subject ‚Äôs response to questions about her health (a standard non -leading question such 
as ‚ÄúHow have you been feeling since your last visit?‚Äù is asked at each visit).  
‚Ä¢ Symptoms spontaneously reported by [CONTACT_423].  
‚Ä¢ Investigations and examinations where the findings are assessed by [CONTACT_2205].  
‚Ä¢ Other information relating to the subject‚Äôs health becoming known to the investigator (e.g. , 
hospi[INVESTIGATOR_059]).  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 55 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_272999]‚Äôs 
eCRF with information about:  
‚Ä¢ Adverse event  
‚Ä¢ Date and time of onset (time can be omitted, if applicable)  
‚Ä¢ Intensity  
‚Ä¢ Causal relationship to IMP  
‚Ä¢ Action taken to IMP  
‚Ä¢ Other action tak en 
‚Ä¢ Date and time of outcome (time can be omitted, if applicable)  
‚Ä¢ Outcome  
‚Ä¢ Seriousness (see 8. 3.1 for definition)  
‚Ä¢ Each of the items in the Adverse Event Log is described in detail in the following sections.  
Adverse Event  
Adverse events should be recorded as diagnoses, if available.  If not, separate signs and symptoms 
should be recorded.  One diagnosis/symptom should be entered per record.  
If a subject suffers from the same adverse event more than once and the subject recovers in between 
the events, the adver se events should be recorded separately.  If an adverse event changes in 
intensity, a worst -case approach should be used when recording the event, i.e. , the highest intensity 
and the longest duration of the event.a 
                                              
a  Exception: if an adverse event with onset before the first IMP administration (i.e ., a pre -treatment adverse 
event) changes in intensity, this must be recorded as two separate events.  The initial adverse event should be 
recorded with outcome ‚Äúnot yet recovered‚Äù and the date and time of outcome is when t he intensity changed.  
The second adverse event should be recorded with date and time of onset when the intensity changed.   
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 56 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  Note the following: A procedure is not an  adverse event; the reason for conducting the procedure is.  
Hospi[INVESTIGATOR_226944]; the reason for hospi[INVESTIGATOR_2138].  Death is not an adverse 
event, but the cause of death is (an exception is sudden death of unknown cause, which is an 
adverse event).  
Date and Time of Onset  
The date of onset is the date when the first sign(s) or symptom(s) were first noted.  If the adverse 
event is an abnormal clinically significant laboratory test or outcome of an examination, the onset 
date is the date the sample was taken or the examination was performed.   
Intensity  
The intensity of an adverse event must be classified using the following 3 -point scale:  
Mild:  Awareness of signs or symptoms, but no disruption of usual activity.  
Moderate:  Event sufficient  to affect usual activity (disturbing).  
Severe:  Inability to work or perform usual activities (unacceptable).  
Causal Relationship to IMP  
The possibility of whether the IMP caused the adverse event must be classified as one of the 
following:  
Reasonable poss ibility:  There is evidence or argument to suggest a causal relationship between the 
IMP and the adverse event.  The adverse event may occur as part of the pharmacological action of 
the IMP or may be unpredictable in its occurrence.  
Examples:  
‚Ä¢ adverse even ts that are uncommon but are known to be strongly associated with IMP 
exposure.  
‚Ä¢ adverse events that are not commonly associated with IMP exposure, but the event occurs in 
association with other factors strongly suggesting causation, such as a strong tempor al 
association or the event recurs on re -challenge.  
No reasonable possibility:    There is no reasonable evidence or argument to suggest a causal 
relationship between the IMP and the adverse event.  
Examples:  
‚Ä¢ known consequences of the underlying disease or condition under investigation.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 57 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ adverse events common in the trial population, which are also anticipated to occur with 
some frequency during the course of the trial, regardless of IMP exposure.  
Action Taken to IMP  
The action taken to the IMP in response to  an adverse event must be classified as one of the 
following:  
‚Ä¢ No change (medication schedule maintained or no action taken)  
‚Ä¢ Withdrawn  
‚Ä¢ Dose Interrupted  
Other Action Taken  
Adverse events requiring therapy must be treated with recognized standards of medical care to 
protect the health and well -being of the subject.  Appropriate resuscitation equipment and medicines 
must be available to ensure the best possible treatment of an emergency situation.  
If medication is administered to treat the adverse event, this m edication should be entered in the 
Concomitant Medication Log . 
Date and Time of Outcome  
The date and time (time can be deleted/omitted, if not applicable) the subject recovered or died.  
Outcome  
The outcome of an adverse event must be classified as one of the following:  
‚Ä¢ Recovered (fully recovered or the condition has returned to the level observed at initiation of 
trial treatment)  
‚Ä¢ Recovered with sequelae (resulted in persistent or significant disability/incapacity)  
‚Ä¢ Recovering  
‚Ä¢ Not yet recovered  
‚Ä¢ Fatal  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 58 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  8.3 Serious  Adverse Events  
8.3.1 Serious Adverse Event Definition  
An event is defined a serious 
adverse event if it:  Guidance  
results in death  Any event resulting in a fatal outcome must be fully 
documented and reported, including deaths occurring within [ADDRESS_273000] always be 
exercised and, when in doubt, the case should be considered 
serious (i.e., if case fulfi lls the criterion for a medically 
important event).  Hospi[INVESTIGATOR_226945].  Hospi[INVESTIGATOR_2144]/or 
surgical operations planned before trial inclusion are not 
conside red adverse events, if the illness or disease existed 
before the subject was enrolled in the trial, provided that the 
condition did not deteriorate during the trial.  
results in persistent or 
significant 
disability/incapacity  Disability/incapacity means a substantial disruption of a 
person‚Äôs ability to conduct normal life functions.  In doubt, the 
decision should be left to medical judgement by [CONTACT_1275].  
is a congenital anomaly/birth 
defect  Congenital anomaly/birth defect observed in any offspring of 
the subject conceived during treatment with the IMP.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 59 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  An event is defined a serious 
adverse event if it:  Guidance  
is an important medical 
event  Important medical events are events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_226946].  
Examples of important medical events include AEs that suggest 
a significant hazard, contraindication or precaution, occurrence 
of malignancy or development of drug dependency or  drug 
abuse.  Medical and scientific judgement should be exercised in 
deciding whether events qualify as medically important.  
Important medical events include any suspected transmission of 
an infectious agent via a medicinal product.  Any organism 
virus or  infectious particle (e.g. , prion protein transmitting 
Transmissible Spongiform Encephalopathy), pathogenic or non -
pathogenic, is considered an infectious agent.  A transmission of 
an infectious agent may be suspected from clinical symptoms or 
laboratory f indings indicating an infection in a subject exposed 
to a medicinal product.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 60 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_273001] be reported immediately  to Ferring Pharmaceuticals as soon as it becomes known to 
the investigator and not later than within 24 hours of the  investigator‚Äôs  knowledge of the occurrence 
of an SAE.  
The investigator is responsible for submitting the completed SAE Report Form with th e fullest 
possible details to the local safety officer at Ferring Pharmaceuticals, Inc. by [CONTACT_87109] 24 hours  of 
his/her knowledge of the SAE and submit all related follow -up information no later than 
[ADDRESS_273002] details below:  
Safety Fax:  
Safety E -mail:  
For questions contact: [CONTACT_25290],  
E-mail:  
Contact [CONTACT_19649]:  
 
Completion of the Demographics, Adverse Events Log, Medical Hist ory Log and Concomitant 
Medication Log is mandatory  for initial reports and for follow -up reports if any changes have been 
made since the initial report.  
Additional information relevant to the SAE such as hospi[INVESTIGATOR_1097], results from investigations, 
e.g., laboratory parameters (that are not already uploaded in the eCRF), invasive procedures, scans 
and x -rays, and autopsy results can be faxed or scanned and e -mailed to Ferring Pharmacovigilance 
using the contact [CONTACT_2213].  In any case , this information must be supplied by [CONTACT_2214].  On any copi[INVESTIGATOR_2146], such details such as subject‚Äôs 
name, address, and hospi[INVESTIGATOR_226947].  
The investigator will supply Ferring and the IEC/IRB with any additional requested information 
such as results of post -mortem examinations and hospi[INVESTIGATOR_1097].  
Expedited Reporting by [CONTACT_226967], unexpecte d and with a reasonable possible 
causality to the IMP  as judged by [CONTACT_226968].  

Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 61 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  The expectedness is assessed by [CONTACT_226969]‚Äôs Brochure.14  
SAEs will be considered reportable regardless of whether or not the IMP was used in accordance 
with the provisions in the protocol, Investigator‚Äôs Brochure and labelling.  
8.[ADDRESS_273003]‚Äôs last visit, the investigator must follow -up on any adverse event classified as 
serious or considered to have a reasonable possible causality to the IMP until it is resolved or until 
the medical condition of the subj ect is stable.  All such relevant follow -up information must be 
reported to Ferring.  If the event is a chronic condition, the investigator and Ferring may agree that 
further follow -up is not required.  
8.4.[ADDRESS_273004]‚Äôs last visit, and he/she assesses the 
SAE to have a reasonable possible causality to the IMP, the case will have to be reported to Ferring, 
regardless of how long after the end of the trial this takes place.  
8.[ADDRESS_273005] per FDA regulations is as follows:  
Unanticipated adverse device effect is any serious adverse effect on health or safety, any life -
threate ning problem or death caused by [CONTACT_1282] a device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of incidence in the application; or any 
other unanticipated serious problem associated with a device  that relates to the rights, safety, or 
welfare of subjects.  Adverse device effects should be collected and assessed as for adverse events 
above.  
The investigator should collect, record, and assess any UADE similar to the directions for adverse 
events abov e.  The investigator must report the adverse device effect to Ferring as described in 
Section  8.3.2  above on the device report form.  In the circumstance that a serious adverse event and 
an UADE occur together, the SAE form should be completed and the device information also 
included . 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 62 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  9 STATI STICAL METHODS  
Details of the statistical methodology will be provided in a separate Statistical Analysis Plan.   
9.1 Determination of Sample Size  
The sample size was determined based on the original fixed parallel group study design. The true 
ovulation rate for LutrePulse OmniPod SC 20  Œºg, 15 Œºg, 10 Œºg, and placebo was assumed to be 
70%, 65%, 60%, and 1%, respectively.  Under these assumptions, a sample size of 14 subjects per 
group (total 56 subjects) will provide at least 80% power to detect differences between LutrePulse 
OmniPod SC 20  Œºg and placebo , 15 Œºg and placebo, and 10  Œºg and placebo in ovulation rate 
separately using  the stratified one-sided Fisher‚Äôs exact tests 19 at an overall one-sided significance 
level of 0.025  with the closed testing procedure (Kong et al., 2005)18 to be used for the primary 
efficacy analysis .   
Approximately 60 subjects will be randomized , assuming up to 4 subjects may be ineligible for the 
full analysis set ( FAS). 
9.[ADDRESS_273006] -baseline discontinuations will be 
summarized by [CONTACT_41794].  The number of subjects screened  and not randomized 
will be presented.  
9.3 Protocol Deviations  
The criteria for protocol deviations considered major with the implication of data exclusions from 
the per -protocol analysis set will be determined before database lock.  
9.4 Analysis Sets  
9.4.1 Intent -to-Treat (ITT) Analysis Set  
All randomized subjects will be included in the ITT analysis set.  
9.4.2 Full Analysis Set (FAS)  
All randomized subjects who are included in the ITT analysis set and received at least 14 days of 
study drug for pi[INVESTIGATOR_226948].  
9.4.3 Modified Intent -to-Treat ( mITT) Analysis Set  
All randomized subjects who received at least one ( 1) pulsatile injection delivery of study drug will 
be included in the mITT  Population.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 63 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  9.4.4 Per Protocol Set (PPS)  
All subjects who are included in the FAS and did not have major protocol deviations will be 
included in the PPS.  
9.4.[ADDRESS_273007] one ( 1) pulsatile injection delivery of study drug will be included 
in the Safety Population.  
9.5 Trial Population  
9.5.1 Demographic and Baseline Characteristics  
Descriptive statistics of demographics and other baseline characteristics will be presented for the 
subjects in the FAS by [CONTACT_1570].  
9.5.2 Medical History and Concomitant Medications  
Medical history will be coded using the Med ical Dictionary for Regulatory Activities (MedDRA).  
Prior and concomitant medications will be summarized by [CONTACT_226970] -therapeutic -chemical (ATC) 
classification 1st level (alphabetically) and ATC classification 2nd level (in decreasing order of 
frequency) . 
9.6 Efficacy Endpoint Assessments  
9.6.1 General Considerations  
A Bayesian adaptive design is adopted to address the following objectives:  
1. Demonstrate superiority of the pooled middle and high doses over placebo  in the 
ovulation rate  
2. Evaluate  the dose -respons e relationship  
The adaptive design includes two interim analyses, conducted after approximately 9 and 12 patients 
per arm enrolling in the study, respectively. The interim analysis provides an opportunit y for 
stoppi[INVESTIGATOR_226949] s utilizing the group sequential strategy or due to 
efficacy futility through Bayesian predictive probability of success. Furthermore, it allows the low 
dose to be dropped following the interim look if it shows a much lower response rate compared 
with the middle and high doses .  
Each interim analysis will result in one of the following possible outcomes:  
1. Continue the trial with all arms  
2. Continue the trial without the low dose  
3. Declare early success, but continue the trial without placebo  
4. Declare early success and stop the trial (both placebo and low dose dropped)  
5. Stop the trial for futility  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 64 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  When  the primary efficacy analysis is not successful at the interim analysis, and if the ovulation rate 
in the low -dose arm is sufficiently low, satisfying  
                                           Rlow < (R high +middle ) ‚Äì 0.2,                                                      (1)  
then the trial will continue without the low dose, resulting in outcome #2 listed above. Note that 
Rlow and Rhigh +middle  in inequality (1) are the observed ovulation rates in the low dose arm and the 
combined middle - and high -dose arms, respectively. However, if inequality (1) is not satisfied, then 
the trial will continue with all arms (outcome #1  listed above ).  
Conversely, wh en success on the primary efficacy analysis is declared at an interim analysis, if the 
response rate in the low -dose arm meets the condition in inequality (1), then the trial is completed at 
this point (outcome #4  listed above ) with dose selection performe d using the ED80 rule (see below).   
In the case the primary efficacy analysis is successful, but the response rate in the low -dose arm is 
within 20% from the combined low - and high -dose success rate, the trial is not stopped 
immediately. Rather, the trial  will continue to enroll additional patients into the low -, middle - and 
high-dose arms to further assess dose responses.  
Finally, the trial may terminate (outcome #5  listed above ) as a result of a low predictive probability 
of success (<0.05) given the da ta collected at the interim analysis.  
At the end of the study, for a trial that achieves efficacy success, the dose to be selected as the 
lowest effective dose is the ED80 dose, defined as the lowest dose that retains at least 80% of the 
largest treatment  effect, i.e.  
                                  (RED80 ‚Äì Rplacebo ) ‚â• (R maximum  ‚Äì Rplacebo ) √ó0.8,                                   (2)  
where R maximum  is the observed ovulation rate in the most effective dose arm, R placebo  is the observed 
ovulation rate in the placebo arm, and R ED80 is the observed ovulation rate in the selected dose arm.  
9.6.[ADDRESS_273008] -baseline P 4 level ‚â•  6 ng/mL  or pregnancy  confirmed by a positive serum Œ≤ -hCG 
(i.e., 2 positive results) or presence of a gestational sac documented by [CONTACT_226951] 
(TVUS) . The denominator will be  based on all subjects in the FAS . Subject s who do not have a 
confirmed pregnancy or at least one P 4 level ‚â•  6 ng/mL due to the P 4 levels never reaching this 
threshold, missing data, early withdrawal, or any other reason will be counted as not having 
ovulation (treatment failure).  
The primary effi cacy analysis will compare the pooled ovulation rate of LutrePulse OmniPod SC 20 
ÔÅ≠g and 15 ÔÅ≠g to placebo. Let Phigh+middle  and  Pplacebo  be the underlying ovulation rates in the 
combined middle - and high -dose arms and the placebo arm, respectively. The hypotheses for the 
one-sided statistical testing are:  
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 65 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  ùêª0:ùëÉ‚Ñéùëñùëî‚Ñé+ùëöùëñùëëùëëùëôùëí ‚â§ ùëÉùëùùëôùëéùëêùëíùëèùëú , 
vs. 
ùêª0:ùëÉ‚Ñéùëñùëî‚Ñé+ùëöùëñùëëùëëùëôùëí > ùëÉùëùùëôùëéùëêùëíùëèùëú . 
The hypotheses are tested using a stratifie d one -sided Fisher‚Äôs exact test (Jung et al., 2014) in the 
FAS including the randomization scheme as the stratification factor. The SAS PROC FREQ with 
permutation -based Cochran -Mantel -Haenszel test with exact p -value derived from all possible 
permutations  will be employed for the calculation of p -value for the stratified Fisher‚Äôs exact test. 
Jung has shown that the stratified Fisher‚Äôs exact test is equivalent to the exact stratified Mantel -
Haenszel test w hen exact p -value is derived from all possible permutations.  
To account for the multiplicities introduced by [CONTACT_226956],  Pocock boundaries 
are used. Thus, the success threshold at each analysis corresponds to a  nominal p -value < 0.0131 to 
maintain an overall one -sided type I error rate of 0.025.   
Further details on the Bayesian adaptive method, including simulation studies assessing design 
operating characteristics, will be provided in the Statistical Analysis Plan (SAP).  
[IP_ADDRESS]  Sensitivity Analyses  
The primary  comparison between the pooled middle - and high-dose arms vs. the placebo arm for 
the primary variab le will be conducted on the following analysis sets  as sensitivity analys es:   
- PPS 
- mITT  
9.6.3 Secondary Efficacy Endpoints  
Clinical and biochemical pregnancy rates , as well as rates of LH surge, will be compared between 
the pooled middle - and high-dose arms vs. the placebo arm  using the same method to be applied to 
the primary efficacy analysis.  
Num bers of follicles with a mean diameter ‚â• 14 mm and dominant follicles with a mean diameter 
‚â• 18 mm in LutrePulse OmniPod SC 20  Œºg, 15 Œºg, and 10  Œºg groups will be compared to those in 
the placebo group using Wilcoxon‚Äôs rank sum test  by [CONTACT_226971] . 
The maximum P 4 level and the mean P 4 level from Days 19, 21, 23, 25 , and 27  values in LutrePulse 
OmniPod SC 20  Œºg, 15 Œºg,  and 10  Œºg groups will be compared to those in placebo group using an 
analysis of covariance (ANCOVA) model including the treatment group and randomization scheme 
as factor s and mean baseline value as covariate.  
The proportion of subjects with at least one ( 1) post-baseline P4 level ‚â•  10 ng/mL will be compared 
to placebo using the same statistical method to be applied to the primary efficacy analysis.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 66 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_273009] value taken on Day 1 and Day 10 , 
respectively, will be presented with descriptive statistics by [CONTACT_1570].  The FSH, LH, and E 2 
levels on Day 1 and Day 10 will be presented graphically by [CONTACT_1570].  
9.7 Extent of Exposure  
The total study treatment exposure, measured by [CONTACT_226972] (calculated by [CONTACT_226973]/times), will be summarized and listed for the Safety Population by [CONTACT_1570].  
9.8 Safety Analysis  
9.8.1 General Considerations  
Complet e listings and summary tables for all safety information, including adverse events, clinical 
laboratory safety data, physical examination, and vital signs , will be presented for subjects who are 
included in the Safety Population.  No formal statistical ana lysis will be performed.  
9.8.2 Adverse Events  
Treatment -emergent adverse events (TEAEs) will be tabulated by [CONTACT_1196] (SOC) and 
Preferred Term (PT) using MedDRA for each treatment group.  The total number of subjects 
reporting a TEAE, the percentage of  subjects (%) with a TEAE, and the number of TEAEs reported 
will be presented.  A TEAE will be any adverse event occurring after the start of IMP and within 
[ADDRESS_273010] -treatment adverse events.  
In addition, TEAEs will be presented by [CONTACT_2235] (relat ionship to the study medication) and 
intensity (severity).  Deaths, serious adverse events, and adverse events leading to discontinuation 
will be listed.  
9.8.[ADDRESS_273011] ics. 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 67 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_273012] of the study afterwards; individual 
patient identification will not be released to anyone who is directly involved in the conduct of the 
study.  
The interim  analysis process, the measures used to pr otect the blind and the integrity of the study, 
the communication plan, and the confidentiality agreement will be described in a separate 
document.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 68 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  10 DATA HANDLING  
10.1 Source Data and Source Documents  
Source Data ‚Äì ICH Definition  
Source data are defined as all information in original records and certified copi[INVESTIGATOR_95937], observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial.  Source data are contained in source document s (original 
records or certified copi[INVESTIGATOR_014]).  
Source Documents - ICH Definition  
Source documents are defined as original documents, data, and records (e.g., hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, subjects‚Äô diaries or evaluat ion checklists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_164372], microfiches, photographic negatives, microfilm 
or magnetic media, x -rays, subject files, and records kept at the pharmacy, at the laboratories and at 
medico -technical departments involved in the clinical trial).  
Trial -Specific Source Data Requirements ‚Äì Ferring  
For each subject  allocated to treatment, the i nvestigator will indicate in the hosp ital/medical source 
records that the subject participates in this trial and the date of obtaining the informed consent. The 
records should document data on the condition of the subject at the time the subject is enrolled in 
the trial to enable verification  of eligibility.  Signed and dated I nformed Consent Forms will be 
stored and archived according to local requirements.  In addition , the following information, at the 
minimum, will also be recorded in the hospi[INVESTIGATOR_307]/medical source records for each subject:  
‚Ä¢ Documentation of signed and dated i nformed consent  
‚Ä¢ Subject‚Äôs name [CONTACT_18131]  
‚Ä¢ Screening/randomization number  
‚Ä¢ Trial identification  
‚Ä¢ Eligibility of participation in the trial (inclusion/exclusion)  
‚Ä¢ Body weight and height  
‚Ä¢ Dosing of IMP/NIMP ‚Äìdate of first a nd last dose  
‚Ä¢ Occurrence of any AEs/SAEs (including description and duration)  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 69 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  ‚Ä¢ Medical history  
‚Ä¢ Date of each visit  
‚Ä¢ Any assessment performed  
‚Ä¢ Any concomitant therapy  
‚Ä¢ Status of the subject at the end of trial  
‚Ä¢ Reason for discontinuation/withdrawal, if applicable  
The following documents collected during the trial should be stored and archived together with the 
subject‚Äôs hospi[INVESTIGATOR_307]/medical records or in the Investigator File as agreed upon prior to the trial start at 
each trial site:  
‚Ä¢ Laboratory print -outs from central  and local  laboratory ‚Äì evaluated, signed, and dated by [CONTACT_92685] a delegated sub-investigator  
‚Ä¢ Patient dispensing logs of IMP  
‚Ä¢ Evaluations of physical examinations  
‚Ä¢ Collection of laboratory samples  
‚Ä¢ Demographics  
‚Ä¢ Known substance abuse  
10.[ADDRESS_273013] research organi zation (CRO) will 
be used for data capture.  The system is validated and access at all levels to the system is 
granted/revoked following Ferring and vendor procedures, in accordance with r egulatory and 
system requirements.  
Data should be entered into the system within [ADDRESS_273014] has attended a visit 
or after the data become available, as applicable.  
The investigator will approve/authorize the eCRF entries for each subj ect with an electronic 
signature [CONTACT_226983] a handwritten signature.   
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 70 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_273015] party CRO.  After the 
trial database is declared clean and released to the statistician, a final copy  of the database will be 
stored at Ferring.  The investigator will also receive a copy of the trial site‚Äôs final and locked data 
(including audit trail, electronic signature [CONTACT_2264]) as write -protected PDF -files produced by [CONTACT_226974].  The PDF -files will be stored on a CD and will be provided to the 
investigator before access to the eCRF is revoked.  
Errors occurring in the eCRF will be corrected electronically.  Such corrections/modifications will 
be automatically tracked by [CONTACT_226975].  
For each subject enrolled, an eCRF will be completed and signed by [CONTACT_941] i nvestigator.  
10.3 Data Management  
A data management plan will be created under the r esponsibility of the Biometrics department.  The 
data management plan will be issued before data collection begins and will describe all functions, 
processes, and specifications for data collection, cleaning and validation.  
The data management plan will de scribe captured methods, who is authori zed to enter the data, 
decisions about ownership of data, source data storage, which data will be transferred (including 
timing of transfers), the origin and destination of the data , and who will have access to the da ta at 
all times.  
10.[ADDRESS_273016], the i nvestigator will provide the Sponsor with additional data relating to the study, or 
copi[INVESTIGATOR_22936], duly anonymized and protected in accordance with applicable 
require ments.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 71 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_273017] and visit the investigator periodically to ensure adherence to the protocol, 
International Conference of Harmonisation -Good Clinical Practice (ICH -GCP), standard operating 
procedures  and applicable regulatory requirements, maintenance of trial -related source records, 
completeness, accuracy and verifiability of eCRF entries compared to source data, verification of 
drug accountability , and compliance to safety reporting instructions.  T he investigator will permit 
the monitor direct access to all source data, including electronic medical records, and/or documents 
in order to facilitate data verifica tion.  The investigator will co operate with the monitor to ensure 
that any discrepancies th at may be identified are resolved.  The investigator is expected to be able to 
meet the monitor during these visits.  When the first subject is randomized at the trial site, a 
monitoring visit will take place shortly afterwards.  For this trial, the freque ncy of the interim 
monitoring visits will be determined by [CONTACT_226976].   
11.2 Audit and Inspection  
The investigator will make all the trial -related source data and records available at any time to 
quality -assurance auditor(s) mandated by [CONTACT_2247], or to domestic/foreign regulatory inspectors or 
representatives from IECs/IRBs who may audit/inspect the trial.  The main purposes of an audit or 
inspection are to assess compliance with the trial protocol and the pri nciples of ICH -GCP including 
the Declaration of Helsinki and all other relevant regulations.  
The subjects must be informed by [CONTACT_226977]/IRBs 
may wish to inspect their medical records.  During audits/inspections , the auditors/inspectors may 
copy relevant parts of the medical records.  No personal identification apart from the 
screening/randomization number will appear on these copi[INVESTIGATOR_014].  
The investigator should notify Ferring without any delay of any inspection by a regulatory authority 
or IEC/IRB . 
11.[ADDRESS_273018] Data  
The investigator will ensure that the confidentiality of the subjects‚Äô data will be preserved.  In the 
eCRF or any other documents submitted to Ferring, the subjects will not be identified by  [CONTACT_111242], but by [CONTACT_226978].  Documents 
that are not for submission to Ferring, e.g., the confidential subject identification code and the 
signed Informed Consent Documents, will be maintai ned by [CONTACT_1210].  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 72 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_273019] OF THE TRIAL  
12.1 Protocol Amendments  
Any change to this protocol will be documented in a protocol amendment, issued by [CONTACT_2247], and 
agreed upon by [CONTACT_226979].  Amendments may be 
submitted for consideration to the approving IEC(s)/IRB(s) and Regulatory Authorities, in 
accordance with local regulations.  Changes to the protocol to eliminate immediate hazard(s) to trial 
subjects may be implemented pri or to IEC(s)/IRB(s) approval/favorable opi[INVESTIGATOR_1649].  
12.[ADDRESS_273020] igator‚Äôs File and in the Trial Master File.  
12.3 Premature Trial Termination  
Both the investigator (with regard to his/her participation) and Ferring reserve the right to terminate 
the trial at any time.  Should this become necessary, the procedures will be agr eed upon after 
consultation between the [ADDRESS_273021] interests of the subjects.  
Regulatory authorities and IECs/IRBs will be informed.  
In addition, Ferring reserves the right to terminate the participation of individual trial sites.  
Conditions that may warrant termination include, but are not limited to, insufficient adherence to 
protocol requirements and failure to enter su bjects at an acceptable rate.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 73 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_273022] the confidentiality of this proprietary information belonging to Ferring 
Pharmaceuticals, Inc.  
13.3 Publications and Public Disclosure  
13.3.1  Publication Policy  
Submission of data for j ournal publication and/or presentation of data to scientific audiences may be 
considered by [CONTACT_226980]. and the investigator(s).  Submission of a manuscript for 
publication will be considered based on the merits of the study results.  The details of specific 
journal authorship will be discussed by [CONTACT_093](s) and the sponsor, with the final decision at 
the discretion of the sponsor.  The investigator(s) agrees the sponsor will have the opportunity to 
review (at least 30 days) all ma nuscripts and abstracts related to this study prior to any submission 
for presentation or publication.  Likewise, if the sponsor prepares a publication based on the results 
of this study, a copy of the manuscript will be provided to the investigator(s) pri or to publication.  
Any external contract research organization or laboratory involved in the conduct of this study has 
no publication rights regarding this study.  
13.3.[ADDRESS_273023] adopted a trials -
registration policy as a condition for publication.  This policy requires that all clinical trials be 
registered in a public, clinical trials registry.  Thus, it is the responsibility of Ferring to register the 
trial in an appropr iate registry  (i.e., www.ClinicalTrials.gov ) that is sponsored by [CONTACT_66121].  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 74 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  14 ETHICAL AND REGULATORY ASPECTS  
14.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB)  
An IEC/IRB will review the protocol and any amendments and advertisements used for recruitment.  
The IEC/IRB will review the Subject Information Sheet and the Informed Consent Form, their 
updates (if any), and any written materials given to the subjects.  A list of all IECs/IRBs to which 
the protoco l has been submitted and the name [CONTACT_226984].  
14.2 Regulatory Authorities Authorization / Approval / Notification  
The regulatory permission to perform the trial will be obtained in accordance with app licable 
regulatory requirements.  All ethical and regulatory approvals must be available before a subject is 
exposed to any trial -related procedure, including screening tests for eligibility.  
14.[ADDRESS_273024] (LSLV) ongoing in the trial.   
For public disclosure purposes,  FDA  uses the ‚Äòprimary completion date‚Äô as a baseline point in time 
from which disclosure reporting of results is required.  The primary completio n date is defined as 
the date of the final data collection specifically regarding the Primary Outcome Measure of a trial.  
(This could be the date the last subject was examined [e.g., LSLV] or the date the subject received 
intervention for the purpose of t he final collection of data for the primary outcome).  
14.[ADDRESS_273025] Information and Consent  
The investigator (or the person delegated by [CONTACT_093]) will obtain a freely given written 
consent from each subject after an appropriate explanation of the aims, methods, anticipated 
benefits, potential hazards, and any other aspects of the trial which are relevant to the subject‚Äôs 
decision to participate.  The trial subject must be given ample time to consider participation in the 
trial, before the consent is obtained.  Th e Informed Consent Documents must be signed and dated 
by [CONTACT_226981] -related procedure, including screening tests for eligibilit y. 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 75 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  The investigator (or the person delegated by [CONTACT_093]) will explain that the subject is 
completely free to refuse to enter the trial or to withdraw from it at any time, without any 
consequences for her further care and without the need to justif y her decision.  The subject will 
receive a copy of the Subject Information and her signed Informed Consent Form.  
If new information becomes available that may be relevant to the trial subject‚Äôs willingness to 
continue participation in the trial, a new Sub ject Information and Informed Consent Form will be 
forwarded to the IEC(s)/IRB(s) (and regulatory authorities, if required).  The trial subjects will be 
informed about this new information and re -consent will be obtained.  
Each subject will be informed that  the monitor(s), quality assurance auditor(s) mandated by [CONTACT_2247], 
IRB/IEC representatives or regulatory authority inspector(s), in accordance with applicable 
regulatory requirements, may review her source records and data.  Data protection will be handled  
in compliance with national/local regulations.  
For subjects not qualified to give their legal consent, the written informed consent must be obtained 
from the legal parent or guardian in accordance with national/local regulations.  If such subjects can 
understand the risks and benefits of the trial, they should also be informed and provide their written 
assent.  
14.[ADDRESS_273026].  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 76 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_273027] in association with the IMP or the 
participation in the trial, Ferring has contracted an insurance that covers the liability of Ferring, the 
investigator and other persons involved in the trial in compliance with the laws in the countries 
involved.  
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 77 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_273028] 15 years (or longer if so 
required by l ocal law ) after the completion or discontinuation of the trial, if no further instructions 
are given by [CONTACT_2247].  
The investigator is responsible for the completion and maintenance of the confidential subject 
identification code that provides the sole link between named subject source records and 
anonymous CRF data for Ferring.  The investigator must arrange for the retention of this Subject 
Identification Log and signed Informed Consent Documents for at least 15 years (or longer if s o 
required by [CONTACT_1769]) after the completion or discontinuation of the trial.  
No trial site document may be destroyed without prior written agreement between the investigator 
and Ferring.  Should the investigator elect to assign the trial documents to ano ther party, or move 
them to another location, Ferring must be notified.  Documents may be transferred to Ferring 
Global Quality Assurance, for example , if the investigator retires and the documents no longer can 
be archived by [CONTACT_779].  
16.2 Trial Master File  
Ferring will archive the trial master file in accordance with ICH -GCP and applicable regulatory 
requirements.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 78 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  17 REFERENCES  
1. Martin KA, Hall J, Adams J, Crowley Jr. WF.  Pulsatile GnRH in hypogonadotropic 
hypogonadism.  In: Filicori M, Flamigni C, eds.  Ovulati on Induction: Basic Science and 
Clinical Advances.  Elsevier Science B.V., 1994:255 -66. 
2. Filicori M, Flamigni C, Dellai P, Cognigni L, Michelacci L, Arnone R, et al.  Treatment of 
anovulation with pulsatile gonadotropin -releasing hormone: prognostic factors  and clinical 
results in 600 cycles.  J Clin Endocrinol Metab.  1994;79:1215 -20. 
3. Christin -Maitre S, de Cr√©cy M, pour le groupe Fran√ßais des pompes √† GnRH.  Pregnancy 
outcomes following pulsatile GnRH treatment: results of a large multicenter retrospective 
study.  Re√ßu le 18 ao√ªt 2006 ; avis du comit√© de lecture le 23 octobre 2006; d√©finitivement 
accept√© le 7 d√©cembre 2006.   
4. Handlesman DJ, Jansen RPS, Boylan LM, Spaliviero JA, Turtle JR.  Pharmacokinetics of 
gonadotropin -releasing hormone: comparison of sub cutaneous and intravenous routes.  J  
Clin Endocrinol Metab.  1984;59:739 -746. 
5. Ferring Study 2005 -06: A Single -Center, Randomized, Open -Label, Pharmacokinetic Study 
of a Pulsatile GnRH Iontophoretic Patch Compared to Pulsatile GnRH Delivered via 
Intravenous  (IV) and Subcutaneous (SC) Pump in Healthy Pre -menopausal Female Subjects.  
12 September 2005.  
6. Ferring Study 2005 -09: A Single -Center, Randomized, Open -Label, Pharmacokinetic Study 
of a Pulsatile GnRH Iontophoretic Patch Compared to Pulsatile GnRH Deliver ed via 
Subcutaneous (SC) Pump in Healthy Pre -menopausal Female Subjects.  5  November  2007.  
7. Ferring Study 000010: A Randomized, Open -Label, [ADDRESS_273029] Crossover Pi[INVESTIGATOR_226950] (via 
OmniPod Pu mp) or Intravenously (via Zyklomat Pump) in Healthy Female Subjects.  
22 October 2012.  
8. Santoro N, Wierman ME, Filicori M, Waldstreicher J, Crowley WF Jr.  Intravenous 
administration of pulsatile gonadotropin -releasing hormone in hypothalamic amenorrhea: 
effects of dosage.  J Clin Endocrinol Metab.  1986;62:109 -116. 
9. LutrePulse ‚Ñ¢ User Guide for OmniPod Pump.  Insulet Corporation, and Ferring, Inc., 2013 . 
10. Provera¬Æ (medroxyprogesterone acetate) package insert.  Pharmacia & UpJohn Company, 
Division of [COMPANY_007], September 2007.  
11. LutrePulse‚Ñ¢ Healthcare Professional (HCP) Quick Reference Guide (Clinical), Ferring 
Inc., 2013.  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 79 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  12. LutrePulse‚Ñ¢ Guide for the Patient (Clinical), Fe rring Inc., 2013.  
13. Clearblue¬Æ.  SPD Swiss Precision Diagnostics GmbH; distributed by [CONTACT_226982] & Gamble, 
2009.   
14. Investigator‚Äôs Brochure.  LutrePulse OmniPod.  Ferring Pharmaceuticals, 2013.  
15. Hurley DM, Clarke IJ, Shelton R, Burger HG.  Subcutaneous administra tion of 
gonadotropin -releasing hormone: absorption kinetics and gonadotropin responses.  J Clin 
Endocrinol Metab.  1987 Jul;65(1):46 -52. 
16. Martin K, Santoro N, Hall J, Filicori M, Wierman M, Crowley WF Jr.  Clinical Review  15: 
Management of ovulatory disorde rs with pulsatile gonadotropin -releasing hormone.  J Clin 
Endocrinol Metab.  1990;71:1081A -1081G.  
17. Golan A, Ron -El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian Hyperstimulation 
Syndrome: An Update Review. Obstetrical and Gynecological Survey. 1989;44 :6:[ADDRESS_273030] drug and placebo. Pharmaceutical Statistics .  2005; 4,25-35. 
19. Jung, S. -H. Stratified Fisher‚Äôs exact test and its sample size calculation. Biometrical J . 
2014; 56. doi: 10.1002/bimj.201300048.  
 
 
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 80 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  18 APPENDICES  
Appendix I ‚Äì Subject‚Äôs Confidential Non -Disclosure Affidavit  
 
CONFIDENTIAL NON -DISCLOSURE AFFIDAVIT  
 
 
I, ____________________________________, agree  to keep confidential my study medication 
assignment provided to me by: _______________________, Study Coordinator.  
 
On this date: _________________________, I agree not to discuss or to disclose the dose of my 
study medication assigned to me with the stud y doctor and anyone other than the above Study 
Coordinator in order to protect the integrity of the data being collected for this clinical research 
study. I understand that the study doctor will not know my study medication assignment and will 
not be allow ed to ask me questions about my study medication assignment. If I have questions 
concerning my study medication assignment, I agree to use the following contact [CONTACT_3031].   
 
Study Contact: _________________________________________  
 
Study Contact [CONTACT_19649]:   __________________________________  
 
SIGNATURES  
I have read this affidavit and understand the above information. The content and meaning of this 
information has been explained to me.   
 
 
_________   _____________________   ___________________________  
Date/T ime  Print Subject Name           [CONTACT_10288]     
 
 
________   _____________________   ___________________________  
Date/Time   Name [CONTACT_226985]/dated confidential non -disclosure affidavit given to subject on (date) __________ 
by ___________ (initials)  
  
Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 81 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: 000070  
No Specified Dosage Form and Strength  
Clinical Trial Protocol - Amendment 7  
Ferring Pharmaceuticals  CONFIDE NTIAL  Appendix II ‚Äì Subject Diary Card  
 
Front of card  
 
                                  Site Number:   ____  ____  ____                          
                            Subject Initials:   ____  ____  ____  
                   Subject  Number:   ____  ____  ____  ____   If you have any questions regarding your 
appointment, please contact [CONTACT_3452].  
Coordinator: _________________________________  
Phone:  _____________________________________  
BRING THIS CARD WITH YOU TO ALL OF YOUR APPOINTMENTS AT THE STUDY SITE.  
Start completing this diary card on your first day of treatment.  
‚Ä¢ Your OmniPod will be applied at the site on Treatment Days 1 and 10.  
‚Ä¢ Change your OmniP od every 4th day at the same time of day +/ - one (1) hour.  
‚Ä¢ Record each Omnipod change on this card on the corresponding day even if the change is  unscheduled.  
‚Ä¢ Record any unscheduled changes, pod malfunctions, applica tion errors or other issues/conc erns in the 
Notes/Comments field.   There is also a field for Additional Notes.   
Day Date  Time of OmniPod Application  Notes/Comments  
Day 1  ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
 
 
 
Day 4  ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
 
 
 
Day 7  ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
 
 
 
Day 10  ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
Were you instructed to start LH testing?  If so, 
don‚Äôt forget to enter your testing information  on 
the back of the card!   
Day 13  ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
Were you instructed to start LH  testing?  If so, 
don‚Äôt forget to enter your testing information  on 
the back of the card!   
Day 16  ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
Were you instructed to start LH testing?  If so, 
don‚Äôt forget to enter your testing information  on 
the back of the card!   
Day 19  ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
Were you instructed to start LH testing?  If so, 
don‚Äôt forget to enter your testing information  on 
the back of the card!   
ADDITIONAL NOTES : 
___________________________________________________________________________________________  
___________________________________________________________________________________________  
___________________________________________________________________________________________  
___________________________________________________________________________________________  
________________________________________________________________________ ___________________  
___________________________________________________________________________________________  
___________________________________________________________________________________________  
____________________________________________________ _______________________________________  
___________________________________________________________________________________________  
___________________________________________________________________________________________  
________________________________ ___________________________________________________________  
___________________________________________________________________________________________  

Date: 06 Dec 2017  
E-Protocol Amendment -[ZIP_CODE]; 1.0 
Supersedes: None  
Page 82 of 82 
 
 
 
 Gonadorelin Acetate, FE 
999037, FE 999903  Trial C ode: [ADDRESS_273031]  
 
 ‚Ä¢ Bring this card with you to all of your appointments.  
‚Ä¢ Change your OmniP od every 4th day at the same tim e of day +/ - one (1) hour.  
‚Ä¢ Record each Omnipod change on this card on the corresponding day even if the change is unscheduled.  
‚Ä¢ Record any unscheduled changes, pod malfunctions, application errors or other issues/concerns in the 
Notes/Comments field.  There  is also a field for Additional Notes.  
Day Date  Time of OmniPod Application  Notes/Comments  
Day 22 ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
Day 25 ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
Day 28 ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
Day 31 ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
Day 34 ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
Day 37 ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
 
Day 37 can be included if applicable.  
Day 
______  ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
This is an unspecified day.  It can be included if 
applicable.  
Day 
______  ____ ____/_______ /____ ____  
    mm              dd             yyyy   ____ _____ :____ _____        
          hr                 min                          ÔÅØ AM 
   ÔÅØ PM  
This is an unspecified day.  It can be included if 
applicable.  
LH Surge Testing 
and Detection  
with Clearblue¬Æ  
Ovulation Kit  Date Clearblue  testing began :         _________ /________ /______ ____ 
                                                                               mm             dd                yyyy  
Date Clearblue testing is positive :  _____ ____ /________ /______ ____  
                                   mm             dd                yyyy  
Sexual Intercourse:    You must  engage in sexual intercourse on the day that your Clearblue test is positive, on 
the day following your positive test, and per your doctor‚Äôs instruction after that.  Enter the date(s) of sexual 
intercourse below for each day that applies.  
Day Date  Did you have sexual intercourse  on this day ? 
Day of positive Clearblue test  ______ /___ ___ / __ ____ 
     mm            dd             yyyy  ÔÅØ Yes        ÔÅØ  No 
[ADDRESS_273032]  ______ /___ ___ / __ ____ 
     mm            dd             yyyy  ÔÅØ Yes        ÔÅØ  No 
[ADDRESS_273033]  ______ /___ ___ / __ ____ 
     mm            dd             yyyy  ÔÅØ Yes        ÔÅØ  No 
[ADDRESS_273034]  ______ /___ ___ / __ ____ 
     mm            dd             yyyy  ÔÅØ Yes        ÔÅØ  No 
ADDITIONAL NOTES :  ___________________________________________________________________________  
___________________________________________________________________________________________  
___________________________________________________________________________________________  
___________________________________________________________________________________________  
________________________________________________________________________ ___________________  